&21),'(17,$/
7KHLQIRUPDWLRQFRQWDLQHGKHUHLQPD\QRWEHXVHGGLVFORVHGRU SXEOLVKHGZLWKRXWWKHZULWWHQFRQVHQWRI%LRYHUDWLY
7KHUDSHXWLFV,QF
%LRYHUDWLY7KHUDSHXWLFV,QF
6HFRQG$YHQXH
:DOWKDP0$
8QLWHG6WDWHV[ZIP_CODE]&2/180%(5 +% 
3+$6(2)'(9(/230(17 
[ZIP_CODE]&2/7,7/( $Q2SHQ/DEHO0XOWLFHQWHU(YDO XDWLRQRIWKH6DIHW\DQG(IILFD F\RI
5HFRPELQDQW&RDJXODWLRQ)DFWRU, ;)F)XVLRQ3URWHLQU),;)F%, ,%LQWKH3UHYHQWLRQ
DQG7UHDWPHQWRI%OHHGLQJLQ3UH YLRXVO\8QWUHDWHG3DWLHQWV:LWK 6HYHUH+HPRSKLOLD%
(8'5$&712  
'$7( $XJXVW 
9HUVLRQ
),1$/
6XSHUVHGHVSUHYLRXV9HUV LRQGDWHG)HEUXDU\
/$5
Protocol 998HB303  Version [ADDRESS_77457] OF ABBREVIATION S AND DEFINITIONS  .................................................11  
3. SYNOPSIS  .................................................................................................................12  
4. STUDY SCHEMATIC AND SCHEDULE OF EVENTS FOR STUDY 
998HB303 ...................................................................................................................17  
4.1. Study Schematic  .........................................................................................................17  
4.2. Schedule of Events .....................................................................................................18  
4.2.1.  Schedule of Events: Screening and Baseline Incremental Recovery Visit  .................18  
4.2.2.  Treatment Period Visits  ..............................................................................................21  
[IP_ADDRESS].  Schedule of Events: Epi[INVESTIGATOR_71195] .........................................21  
[IP_ADDRESS].  Schedule of Events: Exposure Day Milestone Visits .................................................24  
4.2.3.  Schedule of Events: Surgery Visits ............................................................................25  
4.2.4.  Schedule of Events: Immune Tolerance Induction Visits  ..........................................[ADDRESS_77458] S ....................................................................................42  
8.1. Inclusion Criteria  ........................................................................................................42  
8.2. Exclusion Criteria  .......................................................................................................42  
8.3. Minimum Criteria for Enrollment ..............................................................................43  
9. ENROLLMENT AND REGISTRATION PROCEDURES  ......................................44  
9.1. Screening and Baseline  ...............................................................................................44  
9.1.1.  Screening Assessments  ...............................................................................................44  
9.1.2.  Bleeding Epi[INVESTIGATOR_71196]  ......................................45  
9.1.3.  Enrollment of Subjects ...............................................................................................45  
9.1.4.  Baseline Incremental Recovery  ..................................................................................45  
9.2. Registration of Subjects  ..............................................................................................46  
9.3. Blinding Procedures ....................................................................................................46  
10. TREATMENT OF SUBJECTS ..................................................................................47
10.1.  Study Treatment Schedule and Administration ..........................................................47  
10.1.1.  Dosing Based on Actual Potency or Nominal Strength..............................................47  
10.1.2.  Information to be Recorded for Treatment  .................................................................48  
10.2.  Treatment  ....................................................................................................................49  
10.2.1.  Interim Visits  ..............................................................................................................49  
10.2.2.  Assessment of FIX Activity During Interim Visits  ....................................................49  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patient s with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
5 [IP_ADDRESS].  Epi[INVESTIGATOR_71197] (Optional) ...................................................................................49  
[IP_ADDRESS].  Prophylaxis Treatment  ................................................................................................50  
10.2.3.  Treatment of Bleeding Epi[INVESTIGATOR_1841] .................................................................................50  
[IP_ADDRESS].  Definitions of Bleeding Epi[INVESTIGATOR_1865] .................................................................................50  
[IP_ADDRESS].  Information to be Recorded for Bleeding Epi[INVESTIGATOR_1841] ...................................................51  
[IP_ADDRESS].  Determination of the rFIXFc Dose to Treat a Bleeding Epi[INVESTIGATOR_1865] ...............................52  
[IP_ADDRESS].  Procedure to Treat the Bleeding Epi[INVESTIGATOR_1865] ...................................................................52  
[IP_ADDRESS].  Dose and/or Interval Modification Following Bleeding Epi[INVESTIGATOR_1841] .............................52  
10.2.4.  Inhibitor Testing  .........................................................................................................52  
10.2.5.  Anti-rFIXFc Antibody Testing ...................................................................................53  
10.2.6.  Immune Tolerance Induction ......................................................................................54  
[IP_ADDRESS].  Inhibitor Subgroup ......................................................................................................54  
[IP_ADDRESS].  Low Titer Inhibitors ....................................................................................................54  
[IP_ADDRESS].  High Titer Inhibitors  ...................................................................................................54  
[IP_ADDRESS].  Use of By[CONTACT_71328]  ............................................................................................54  
[IP_ADDRESS].  Immune Tolerance Induction Therapy .......................................................................55  
[IP_ADDRESS].  Treatment of Bleeding Epi[INVESTIGATOR_71198] .......................................................................................................................57  
10.2.7.  Surgery ........................................................................................................................57  
[IP_ADDRESS].  Surgical Period  ............................................................................................................58  
[IP_ADDRESS].  Dosing During Surgery ...............................................................................................58  
[IP_ADDRESS].  Rehabilitation Period  ..................................................................................................59  
10.3.  Treatment Precautions  ................................................................................................59  
10.4.  Modification of Dose and/or Treatment Schedule ......................................................59  
10.5.  Non-Medical Treatment With rFIXFc  ........................................................................59  
10.6.  End of Treatment ........................................................................................................59  
10.7.  Treatment Compliance  ................................................................................................60  
10.8.  Concomitant Therapy and Procedures ........................................................................60  
10.8.1.  Concomitant Therapy .................................................................................................60  
10.8.2.  Concomitant Procedures .............................................................................................61  
10.9.  Continuation of Treatment ..........................................................................................61  
11. WITHDRAWAL OF SUBJECTS F ROM THE STUDY  ...........................................62
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patient s with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
6 12. STUDY TREATMENT MANAGEMENT  ................................................................64
12.1.  rFIXFc (BIIB029)  .......................................................................................................64  
12.1.1.  rFIXFc Preparation  .....................................................................................................64  
12.1.2.  rFIXFc Storage at Site  ................................................................................................65  
12.1.3.  rFIXFc Handling and Disposal ...................................................................................65  
12.1.4.  rFIXFc Accountability  ................................................................................................65  
13. EFFICACY AND ACTIVIT Y ASSESSM ENTS .......................................................66
13.1.  Clinical Efficacy Assessments  ....................................................................................66  
13.2.  Laboratory Efficacy Assessments  ...............................................................................66  
13.3.  Pharmacokinetic Assessments  ....................................................................................66  
13.4.  Pharmacodynamic Assessments  .................................................................................67  
13.5.  Additional Assessments  ..............................................................................................67  
13.5.1.  Factor 9 Genotypi[INVESTIGATOR_007] (Optional) ..................................................................................67  
13.5.2.  Health Outcomes Related to Hemophilia  ...................................................................67  
14. SAFETY ASSESSMENTS  ........................................................................................69
14.1.  Clinical Safety Assessments  .......................................................................................69  
14.2.  Laboratory Safety Assessments  ..................................................................................69  
14.3.  rFIXFc-Specific Safety Assessments  .........................................................................69  
14.4.  Additional Assessments  ..............................................................................................70  
14.5.  Archive Samples  .........................................................................................................70  
14.5.1.  Archive Plasma Samples  ............................................................................................70  
14.6.  Sample Volumes  .........................................................................................................70  
15. SAFETY DEFINITIONS, RECORDING, REPORTING , AND
RESP
ONSIBILITIES  .................................................................................................72  
15.1.  Definitions  ..................................................................................................................72  
15.1.1.  Adverse Event  .............................................................................................................72  
15.1.2.  Serious Adverse Event ................................................................................................72  
[IP_ADDRESS].  Serious Pretreatment Event  .........................................................................................73  
15.2.  Safety Classifications  ..................................................................................................73  
15.2.1.  Investigator Assessment of Events .............................................................................73  
15.2.2.  Relationship of Events to Study Treatment ................................................................74  
15.2.3.  Severity of Events  .......................................................................................................74  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patient s with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
7 15.2.4.  Expectedness of Events ..............................................................................................74  
15.3.  Monitoring and Recording Events ..............................................................................75  
15.3.1.  Adverse Events  ...........................................................................................................75  
15.3.2.  Serious Adverse Events ..............................................................................................75  
15.3.3.  Immediate Reporting of Serious Adverse Events .......................................................76  
[IP_ADDRESS].  Deaths .........................................................................................................................77  
15.3.4.  Suspected Unexpected Serious Adverse Reactions  ....................................................77  
15.4.  Procedures for Handling Special Situations ...............................................................77  
15.4.1.  Pregnancy  ...................................................................................................................77  
15.4.2.  Overdose .....................................................................................................................78  
15.4.3.  Medical Emergency  ....................................................................................................78  
15.4.4.  Unblinding for Medical Emergencies .........................................................................78  
15.5.  Safety Responsibilities  ................................................................................................78  
15.5.1.  Investigator Responsibilities  .......................................................................................78  
15.5.2.  Bioverativ Responsibilities  .........................................................................................79  
16. STATISTICAL METHODS  AND DETERMINATION OF  SAMPLE SIZE  ...........80  
16.1.  Demography and Baseline Disease Characteristics  ....................................................80  
16.2.  Efficacy .......................................................................................................................80  
16.2.1.  Analysis Population ....................................................................................................80  
16.2.2.  General Methods of Analysis .....................................................................................81  
16.2.3.  Analysis of Efficacy Endpoints ..................................................................................81  
16.2.4.  Additional/Exploratory Analysis of Efficacy Endpoints ............................................82  
16.3.  Pharmacokinetics  ........................................................................................................82  
16.4.  Pharmacodynamics  .....................................................................................................82  
16.5.  Safety ..........................................................................................................................82  
16.5.1.  Analysis Population ....................................................................................................82  
16.5.2.  Methods of Analysis ...................................................................................................83  
[IP_ADDRESS].  Occurrence of Inhibitor Development  ........................................................................83  
[IP_ADDRESS].  Adverse Events  ...........................................................................................................83  
[IP_ADDRESS].  Other Safety Parameters  .............................................................................................[ADDRESS_77459] Research Organization  .................................................................................89  
19.1.2.  Interactive Voice and Web Response System  ............................................................89  
19.1.3.  Electronic Data Capture  ..............................................................................................89  
19.1.4.  Central Laboratories for Laboratory Assessments  .....................................................89  
19.2.  Study Committees  .......................................................................................................89  
19.2.1.  Independent Data Safety Monitoring Committee .......................................................89  
19.3.  Changes to Final Study Protocol ................................................................................90  
19.4.  Ethics Committee Notification of Study Completion or Termination  ........................90  
19.5.  Retention of Study Data ..............................................................................................90  
19.6.  Study Report Signatory...............................................................................................90  
20. REFERENCES  ...........................................................................................................91  
21. SIGNED AGREEMENT OF THE STUDY PROTOCOL  .........................................94  
APPENDIX A.  RFIXFC DOSING GUIDELINES FOR BLEEDING EP ISODES ...................95  
APPENDIX B.  ASSESSMENT OF RESPON SE TO BLEEDING  ...........................................96  
APPENDIX C.  PHYSICIAN‚ÄôS GLOBAL A SSESSMENT  .......................................................[ADDRESS_77460] OF TABLES  
Table 1:  Comparison of rFIXFc PK Parameters by [CONTACT_71329]: Geometric Mean 
(95% Confidence Interval [CI]) ..................................................................................33  
Table 2:  Examples of Recommended Blood Draw Volume Limits .........................................[ADDRESS_77461] OF FIGURES  
Figure 1:  Study Design  ...............................................................................................................[ADDRESS_77462] 
Waltham, MA [ZIP_CODE]  
 
 
 
 
For urgent medical issues in which the study‚Äôs Medical Director should be contact[INVESTIGATOR_530], please 
refer to the Study Reference Guide‚Äôs Official Study Contact [CONTACT_71330]. 
Bioverativ  may transfer any or all of its study -related responsibilities to a contract research 
organization (CRO) and other third parties; however, Bioverativ  retains overall accountability for 
these activities.  

Protocol 998HB303  Version [ADDRESS_77463] research organization  
DHA Directions for Handling and Administration  
DLT dose-limiting toxicity  
DSMC Data Safety Monitoring Committee  
eCRF electronic case report form  
ED exposure day  
EMA European Medicines Agency  
EOS end of study  
EPD electronic patient diary  
ET early termination  
FAS Full Analysis Set 
FcRn neonatal Fc receptor  
FIX coagulation factor IX  
GCP Good Clinical Practice  
HIV human immunodeficiency virus  
ICF informed consent form  
ICH International Council for  Harmonisation  
IgG1 immunoglobulin G1  
IR incremental recovery  
ITI immune tolerance induction  
IU international u nits 
IV intravenous  
IXRS Interactive Voice/Web Response System  
pdFIX plasma-derived factor IX 
PHI protected health information  
PK pharmacokinetic , pharmacokinetic s 
PTP previously treated patient  
PUP previously untreated patient  
rFIX recombinant coagulation factor IX 
rFIXFc recombinant coagulation factor IX Fc fusion protein  
SAE serious adverse event  
SAP statistical analysis plan  
S[LOCATION_003]R suspected unexpected serious adverse reaction  
t¬Ω half-life 
WHO World Health Organization  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patient s with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
12 3. SYNOPSIS  
This is a brief summary.  For details refer to the body of the protocol. 
Protocol Number: 998HB303 
Protocol Title: An Open-Label, Multicenter Evaluation of the Safety and 
Efficacy of Recombinant Coagulation Factor IX Fc Fusion 
Protein (rFIXFc; BIIB029) in the Prevention and Treatment 
of Bleeding in Previously Untreated Patients W ith Severe 
Hemophilia  B 
Version Number: 3 
Name [CONTACT_71413] : Recombinant coagulation factor IX Fc fusion protein 
(rFIXFc; BIIB029)  
Study Indication:  Hemophilia B  
Phase of Development: 3 
Rationale for the Study: The use of a prophylaxis regimen in young children starting prior to the onset of frequent joint bleeding is currently the 
recommended standard of care in hemophilia due to the 
demonstrated benefit on long- term outcomes  [Aznar 2000; 
Manco-Johnson 2007; Molho 2000] . Currently available 
coagulation factor IX (FIX) replacement therapi[INVESTIGATOR_71199] -life requiring intravenous 
(IV) administration  up to 3 times per week.   
The purpose of this study is to investigate the safety and efficacy of rFIXFc in previously untreated patients (PUPs) in accordance with the European Medicines Agency (EMA) 
Committee for Medicinal Products for Human Use (CHMP) guideline on clinical investigation of recombinant and human plasma -derived factor IX products [EMA 
(EMA/CHMP/BPWP/144552/2009) 2011] .  
Study Objectives and Endpoints: Objectives  
The primary objective of the study is to evaluate the safety 
of rFIXFc in previously untreated subjects with severe 
hemophilia B.   
 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patient s with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
13 The secondary objectives of th e study are as follows:  
‚Ä¢ To evaluate the efficacy of rFIXFc in the 
prevention and treatment of bleeding epi[INVESTIGATOR_71200].  
‚Ä¢ To evaluate rFIXFc consumption for prevention 
and treatment of bleeding epi[INVESTIGATOR_71201] .  
The exploratory objective of the study is  to evaluate the 
effect of rFIXFc based on patient -reported outcomes and 
health resource utilization.   
Endpoints  
The primary endpoint of the study is the occurrence of 
inhibitor development.  
The secondary  endpoints of the study are as follows: 
‚Ä¢ the annualized number of bleeding epi[INVESTIGATOR_1841] 
(spontaneous and traumatic) per subject.  
‚Ä¢ the annualized number of spontaneous joint 
bleeding epi[INVESTIGATOR_71202].  
‚Ä¢ assessments of r esponse to treatment with 
rFIXFc for bleeding epi[INVESTIGATOR_1841], using the 4-point 
bleeding response scale (Investigator assessment 
for bleeding epi[INVESTIGATOR_71203] ; parent 
or caregiver assessment for all other bleeding 
epi[INVESTIGATOR_1841]).  
‚Ä¢ the total number of exposure days (EDs) per 
subject per year.   
‚Ä¢ total annualized rFIXFc con sumption per subject 
for the prevention and treatment of bleeding 
epi[INVESTIGATOR_1841].  
‚Ä¢ the number of injections and dose per injection 
of rFIXFc required to resolve a bleeding epi[INVESTIGATOR_1865].  
‚Ä¢ rFIXFc incremental recovery .  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patient s with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
14  
The exploratory endpoints include, but are not li mited to: 
‚Ä¢ health outcomes 
Study Design:  An open-label, single -arm, multicenter study evaluating the 
safety and efficacy of rFIXFc in previously untreated 
subjects with severe hemophilia B when used according to 
local standard of care for implementation of a prophylaxis 
regimen, including an optional preceding epi[INVESTIGATOR_49564] 
(on-demand) treatment regimen.  Following confirmation of 
eligibility , the Investigator has the option to treat the subject 
epi[INVESTIGATOR_71204] a prophylaxis regimen.  The 
duration of epi[INVESTIGATOR_71205]‚Äôs discretion, in accordance with local standard of care.  The 
study will end when at least [ADDRESS_77464] a 
positive low titer inhibitor that is not reliably controlled with 
rFIXFc or a positive high titer inhibitor .  
Adjustments to the dose and interval of rFIXFc can be made 
in this study based on available pharmacokinetic (PK) data, 
subsequent FIX activity levels, level of physical activity, 
and bleeding pattern, in accordance with local standar ds of 
care for a prophylactic regimen.   
Subjects may be enrolled and receive study drug after 
samples have been drawn for factor IX activity and inhibitor 
testing at the central laboratory, and diagnosis of severe 
hemophilia B with ‚â§2% factor IX activity has been 
established based on local laboratory values  or in the 
documented medical record. However, any such subject must be withdrawn if the central laboratory screening results 
indicate factor IX activity >2%, or a positive inhibitor. 
Rationale for Dose and 
Schedule Selection:  
Results of the Phase 1/2a study (S tudy SYN-FIXFc-07-001) 
evaluating the safety and PK of a single dose of rFIXFc suggested that rFIXFc is well tolerated when given as a 
single dose at doses ranging from 1 to 100 internati onal 
units (IU)/kg. In the completed Phase 3 study 
(Study 998HB102),  multiple doses between 20 and 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patient s with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
15 100 IU/kg were generally well tolerated, with an  adverse 
event profile generally consistent with that expected in 
patients with hemophilia B.   
The recommended starting prophylactic dose of rFIXFc in 
this study, approximately 50 IU/kg weekly, is based on the 
data from the Phase 1/2a and Phase 3 studies (including 
pediatric PK data from subjects <12 years of age ) and 
knowledge of increased clearance and decreased recovery  of 
factor concentrates in children.  This dose is predicted to 
maintain trough levels >1% in 99% of pediatric subjects.  
The dose for treatment of bleeding epi[INVESTIGATOR_71206] 30% to 100%, in 
accordance with local standards.   
Study Location:  Multinational  
Number of Planned Subjects: At least [ADDRESS_77465] 50 EDs with 
rFIXFc at the end of the study.   
Study Population: This study will be conducted in male, previously untreated 
subjects <18  years of age with severe hemophilia B.  
Detailed entry criteria are described in the protocol.   
Treatment Groups: This is a single -arm study. Subjects developi[INVESTIGATOR_71207].  
Duration of Treatment and 
Follow-up: Individual subject study participation is expected to be approximately [ADDRESS_77466] udy treatment , unless withdrawal from 
the study occurs, or the end of study is declared.  
Statistical Methods:  In general, all statistical analyses will be descriptive in nature. No formal comparison is planned and no hypothesis 
will be formally tested.  Continuous variables will be 
summarized and presented by [CONTACT_46932], mean, median, standard deviation, minimum, and 
maximum.  Categorical variables will be summarized by [CONTACT_71331].   
Subjects with at least 1 dose of rFIXFc (study drug and/or commercially available rFIXFc) will be included in the 
Safety Analysis Set. Subjects with at least 1 dose of rFIXFc 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patient s with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
16 study drug will be included in the Full Analysis Set (FAS).  
Subjects with at least 1 dose of rFIXFc study drug and who 
meet the eligibility criteria (with screening FIX activity and 
inhibitor test results confirmed by [CONTACT_2237]) will be included in the Supporting Analysis Set. Efficacy 
analyses will be based on the FAS. Safety analyses will be 
based on the Safety Analysis Set, with some analyses based on the Supporting Analysis Set, as appropriate. Subjects 
developi[INVESTIGATOR_007] a confirmed positive inhibitor test after exposure 
to rFIXFc study drug will have their efficacy and safety data 
included up to the time of the last negative inhibitor test; 
efficacy and safety data collected after the time of the last 
negative inhibitor test will be summarized separately.  
Summary statistics will be presented for safety and  efficacy 
endpoints. The proportion of subjects developi[INVESTIGATOR_71208] a 95% confidence interval.  For 
efficacy purposes, the number of bleeding epi[INVESTIGATOR_71209]. The summary statistics of bleed ing epi[INVESTIGATOR_1865] s per 
person-year and subject‚Äôs response to treatment will be 
presented separately for epi[INVESTIGATOR_71210].  
Other statistical analyses may be conducted for exploratory 
purposes.  
Interim Analysis: No interim analyses are planned for this study. 
Sample Size D etermination: Because the size of the hemophilia population is limited, the 
sample size is based on clinical rather than statistical considerations. Taking into account the CHMP Guideline 
[EMA (EMA/CHMP/BPWP/144552/2009) 2011]  and in an 
effort to enroll a sufficient number of subjects to assess the 
efficacy and safety of rFIXFc in this population of primarily  
very young children, approximately [ADDRESS_77467] 20 subjects with no less than 50 
EDs by [CONTACT_71332].  
Study Stoppi[INVESTIGATOR_1869]: Study stoppi[INVESTIGATOR_71211] : 
‚Ä¢ unacceptable inhibitor incidence as determined 
by [CONTACT_71333]  
‚Ä¢ detection of an unexpected, serious, or unacceptable risk to the study subjects 
3URWRFRO+% 9HUVLRQ
6DIHW\DQG(IILFDF\RIU),;)FLQ3UHYLRXVO\8QWUHDWHG3DWLHQWV ZLWK+HPRSKLOLD%
&21),'(17,$/
7KHLQIRUPDWLRQFRQWDLQHGKHUHLQPD\QRWEHXVHGGLVFORVHGRU SXEOLVKHGZLWKRXWWKHZULWWHQFRQVHQWRI%LRYHUDWLY
7KHUDSHXWLFV,QF
678'<6&+(0$7,&$1'6&+('8/(2)(9(176)25
678'<+%
6WXG\6FKHPDWLF
)LJXUH 6WXG\'HVLJQ 
%LUWK2SWLRQDO(SLVRGLF
2Q'HPDQG5HJLPHQ3URSK\OD[LV
5HJLPHQ
6FUHHQLQJ
9LVLWDE&RQILUPDWLRQRI
(OLJLELOLW\DE,QLWLDWLRQRI
3URSK\OD[LV5HJLPHQ
6XEMHFWVZKR'HYHORS,QKLELWRUV'XULQJWKH6WXG\H)LQDO9LVLWDQG
)ROORZXS&DOO¬îLQMHFWLRQVRI
FRPPHUFLDOO\DYDLODEOH
U),;)FD
ZHHNVF
,7,5HJLPHQWR
GD\V
(7(26GPRQWKV
PD[LPXP)LQDO9LVLWDQG
)ROORZXS&DOO
WR
GD\V%DVHOLQH,59LVLWE
(26 HQGRIVWXG\(7 (DUO\7HUPLQDWLRQ,5 LQFUHPHQWDOUH FRYHU\,7, LPPXQHWROHUDQFHLQGXFWLRQ
D6XEMHFWVPD\QRWHQWHUWKHVWXG\LIWKH\KDYHUHFHLYHG!LQMH FWLRQVRIFRPPHUFLDOO\DYD LODEOHU),;)FSULRUWR
FRQILUPDWLRQRIHOLJLELOLW\RUFRPPHUFLDOO\DYDLODEOHU),;)FP RUHWKDQGD\VSULRUWRWKHILUVW6FUHHQLQJ9LVLW
E6FUHHQLQJ9LVLWDQG%DVHOLQH,59LVLWPD\EHSHUIRUPHGDVVH SDUDWHYLVLWV25DOODFWLYLWLHVQHFHVVDU\IRU
VFUHHQLQJFRQILUPDWLRQRIHOLJLELOLW\DQGWKH%DVHOLQH,59LV LWPD\EHSHUIRUPHGDWWKHVDPHYLVLW
F,IVFUHHQLQJDVVHVVPHQWVFDQQRWEHFRPSOHWHGZLWKLQZHHNVV RPHDVVHVVPHQWVPD\QHHGWREHUHSHDWHGDV
GHVFULEHGLQ6HFWLRQ 
G7KHPRVWFRPPRQVFHQDULRIRUWKHHQGRIWUHDWPHQWLVVKRZQKR ZHYHUWKHHQGRIWUHDWPHQWPD\RFFXUXQGHU
RWKHUFLUFXPVWDQFHVDVGHILQHGE\WKHSURWRFROIRUH[DPSOHZK HQWKHHQGRIWKHVWXG\LVGHFODUHGRUXSRQHDUO\
ZLWKGUDZDORIDVXEMHFWZKRGRHVQRWPHHWWKHFULWHULDIRUVXFF HVVIXO,7,6HFWLRQ 
H6HH6HFWLRQ IRUFULWHULDRIHOLJLELOLW\WRUHFHLYHWKH,7,UHJLPHQ
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
18 4.2. Schedule of Events  
4.2.1. Schedule of Events: Screening and Baseline Incremental Recovery Visit  
Tests and Assessments  Screeninga Baseline Incremental Recovery Visitb 
Predose Postdose 
Informed Consent  X   
Demographicsc X   
Medical and Surgical Historyd X   
Physical Examinatione X   
Height X   
Weight X X  
Vital Signsf X X X 
Health Outcome  X  
Hematolog yg X   
Blood Chemi stryh X   
Viral Analysisi X   
Nijmegen -Modified Bethesda Assay (Inhibitor Assay)j Xk Xl  
FIX Activity  Xk   
FIX Activity for Incremental Reco verym  Xl X 
Anti-rFIXFc Antibod yj X Xl  
F9 Genotypi[INVESTIGATOR_71212]  X  
Injection Site Inspectio no   X 
EPD Review, including rFIXFc Dosing Accountabi lityp  Monitor and record at all visits  
rFIXFc Clinic Dosing   X 
Assessment of Response to Individual Bleeding Epi[INVESTIGATOR_71213]/Parent/Careg iverq  Monitor and record at all visits 
Physician‚Äôs Assessment of Response to Individual 
Bleeding Epi[INVESTIGATOR_71214] X <<<<ONGOING:  Monitor and record at 
all visits>>>> 
Serious Adverse Eve ntsr X <<<<ONGOING:  Monitor and record at 
all visits>>>> 
Concomitant Therapy/Procedures Recor dings X <<<<ONGOING:  Monitor and record at 
all visits>>>>  
AE = adverse event; DHA=Directions for Handling and Administration; ED = exposure day;  EPD = electronic 
patient diary; ET = Early Termination; F9 = target gene for hemophilia B; FIX = coagulation factor IX; HIV = 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
19 human immunodeficiency virus; ICF = informed consent form; IR = incremental recovery; rFIXFc = recombinant 
coagulation factor IX Fc fusion protein ; SAE = serious adverse event  
 
a If screening assessments cannot be completed within 8 weeks, some assessments may need to be repeated as 
described in  Section 7.3.1. 
b The Baseline IR Visit activities may be completed on the same day as Screening, or they may be completed as part 
of a separate visit (as shown) or at an unscheduled visit . Baseline IR requires a washout from rFIXFc of at least 72 
hours prior to the predose sample collection.  
c Race and ethnicity will be included among the demographic data collected in this study, for reasons described in  
Section 17.4.  
d Medical and surgical history includes any significant medical condition and/or any significant surgical histories, 
plus the following: HIV infection status (if positive, viral load, cluster of differentiation 4 [CD4] count, and 
platelets; based on laboratory results within the last 6 months), hepatitis B infection status, hepatitis C infection status, medication history, and any other congenital immunodeficiency.  Medical history should also include any 
dosing with commercially available rFIXFc fo r bleeding epi[INVESTIGATOR_71215] [ADDRESS_77468] annually; more frequent physical examinations 
may be performed at the Investigator‚Äôs discretion, according to their standard of care.  
f Vital signs include blood pressure, pulse rate, respi[INVESTIGATOR_697], and temperature (¬∞C).  Postdose assessments 
following in -clinic injections should be taken approximately [ADDRESS_77469] 72 hours  
(including prior to collection of the Screening sample, if there was prior dosing with FIX) . Samples for anti-
rFIXFc antibody testing will be collected at the same timepoint when any samples are collected for inhibitor 
testing, including confirmatory and unscheduled inhibitor tests.  An unscheduled visit may be required to obtain 
samples to confirm a positive inhibitor test result.  
k See minimum criteria for enrollment, Section 8.3.  
l The predose sample collection for FIX activity, anti -rFIXFc antibody, and inhibitor testing are only required for 
subjects who received at least [ADDRESS_77470] be calculated and recorded using the actual potency as 
described in the DHA and i n Section 10.1.1 of the protocol . The dose of factor for the IR baseline is 50 IU/kg 
(Section 9.1.4). Samples for incremental recovery calculations to be taken when the subject is in a non -bleeding 
state and after at least a 72-hour washout . Blood samples will be taken predose  within 30 minutes prior to the  start 
of rFIXFc injection ) and postdose 10 (¬±5) minutes after the end of the rFIXFc injection .  
n If genotype is not known and the parent/legal guardian  provides separate consent for genotypi[INVESTIGATOR_007], a sample will be 
drawn for analysis during the Predose Baseline IR Visit.  If blood volume is limiting, this a ssessment may be 
performed at a subsequent visit ( Section [IP_ADDRESS] and Section  [IP_ADDRESS]). The subject‚Äôs  parent/legal guardian  may 
provide consent in order to receive this testing at any time during the Treatment Period.   
o Injection site inspection is to be performed after each injection of rFIXFc that the subject receives during a site 
visit. 
p The subject/parent/caregiver must enter dosing information into the EPD as soon as possible after an injection 
and within a maximum of 7 days  following the injection ( Section 10.1.2). It is recommended that 
subjects/parents/caregivers enter dosing information immediately after an injection.  
q It is recommended that the subject/parent/caregiver enter the response to a bleeding epi[INVESTIGATOR_71216]  (Section [IP_ADDRESS]). 
Protocol 998HB303  Version [ADDRESS_77471] milk is derived from a source other than the mother or 
the mother has not consented.   
  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
21 4.2.2. Treatment Period Visits  
Subjects on epi[INVESTIGATOR_71217] (Section [IP_ADDRESS]), as well as follow up at specific exposure day ( ED) 
milestones ( Section [IP_ADDRESS]). Subjects on immune tolerance induction therapy ( ITI) will 
participate in an ITI -specific schedule of interim visits ( Section 4.2.4). Subjects requiring surgery 
will also participate in specialized visits ( Section 4.2.3). 
[IP_ADDRESS].  Schedule  of Events:  Epi[INVESTIGATOR_71218].  Subjects on epi[INVESTIGATOR_71219]. 
Tests and Assessments  Interim Visits  
ET/
EOS 
Visit Safety 
Follow-Upc Epi[INVESTIGATOR_71220] 12 (¬±2) weeksa Prophylaxis Regimen  Visits 
every 12 (¬±2) weeksb 
Predose Postdose Predose Postdose 
Physical Examinationd     X  
Height     X  
Weight X  X  X  
Vital Signse X X X X X  
Health Outcomef X  X  X  
Hematologyg X  X  X  
Blood Chemistryh X  X  X  
Nijmegen -Modified 
Bethesda Assay (Inhibitor 
Assay)i,j X  X  X  
FIX Activityk   X X   
Anti-rFIXFc Antibodyi X  X  X  
F9 Genotypi[INVESTIGATOR_71221]   X  X   
Physician‚Äôs Global 
Assessment of Response  X  X    
EPD Review, including 
rFIXFc Dosing 
Accountabilitym <<<<<<<<<<<<<<<<<< ONGOING >>>>>>>>>>>>>>>>  
rFIXFc Clinic Dosi ngn X X   
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
22 Tests and Assessments  Interim Visits  
ET/
EOS 
Visit Safety 
Follow-Upc Epi[INVESTIGATOR_71220] 12 (¬±2) weeksa Prophylaxis Regimen  Visits 
every 12 (¬±2) weeksb 
Predose Postdose Predose Postdose 
Assessment of Response to 
Individual Bleeding 
Epi[INVESTIGATOR_71222]/Parent/Caregivero 
  
<<<<<<<<<<<<<<<<<< ONGOING >>>>>>>>>>>>>>>> 
 
Physician‚Äôs Assessment of 
Response to Individual 
Bleeding Epi[INVESTIGATOR_71223]  <<<<<<<<<<<<<<<<<< ONGOING >>>>>>>>>>>>>>>>  
Adverse Eventso,p  <<<<ONGOING:  Monitor and record at all visits; telephone call every month >>>> 
Serious Adverse Eventso,p  <<<<ONGOING:  Monitor and record at all visits; telephone call every month >>>> 
Concomitant Therapy/Procedures 
Recordingq <<<<ONGOING:  Monitor and record at all visits; telephone call every month >>>> 
AE = adverse event ; DHA=Directions for Handling and Administration; ED = exposure day; EOS = end of study; 
EPD = electronic patient diary; ET = early termination; F9 = target gene for hemophilia B; FIX = coagulation factor 
IX; HIV = human immunodeficiency virus; ICF = informed consent form; rFIXFc = recombinant coagulation factor 
IX Fc fusion protein; SAE = serious adverse event  
a For subjects on epi[INVESTIGATOR_71224], blood draws will 
only be required every [ADDRESS_77472] should continue to participate in interim visits every 12 ¬± 2 weeks (per the prophylaxis 
regimen).  
c A follow-up telephone  call or in perso n visit is required 14 (+7) days after the last dose of rFIXFc to monitor AEs, 
SAEs, and concomitant medications and procedures.  This [ADDRESS_77473] annually; more frequent physical examinations 
may be performed at the Investigator‚Äôs discretion, according to their standard of care.  
e Vital signs include blood pressure, pulse rate, respi[INVESTIGATOR_697], and temperature (¬∞C) . Postdose assessments 
following in -clinic injections should be taken approximately [ADDRESS_77474] 72 hours . 
Samples for anti -rFIXFc antibody testing will be collected at the same timepoint when any samples are collected 
for inhibitor testing, including confirmatory a nd unscheduled inhibitor tests.  Testing for inhibitors and anti-rFIXFc 
antibodies will also be performed at specific ED milestones , see Section [IP_ADDRESS]. An unscheduled  visit may be 
required to obtain samples for repeat inhibitor and anti -rFIXFc antibody testing under this protocol to confirm a 
Protocol 998HB303  Version [ADDRESS_77475] at the ET/EOS Visit is not evaluable.  In addition, if inhibitor 
development is suspected at any time during the study (e.g., the expected plasma FIX activity levels are not 
attained or if bleeding is not controlled with an expected dose), samples will be collected for inhibitor testing by 
[CONTACT_71334] -rFIXFc antibodies . 
j If the subject‚Äôs genotype was not already known at Screening and the sample could not be drawn due to blood 
volume limitations at the Predose Baseline IR Visit, th is assessment may be performed at any other v isit. If the 
subject develops an inhibitor on the study, a sample may be drawn for this testing at any time during the Treatment Period. The parent/legal guardian  must provide separate consent for genotypi[INVESTIGATOR_007].   
k Samples for FIX activity will only be taken if the subject receives an rFIXFc injection during a site visit and is in a 
non-bleeding state , after a washout  of at least 72 hours . Predose sample is to be collected within 30 minutes prior 
to the start of the rFIXFc injectio n; postdose sample is to be taken 10 (¬±5) minutes after the end of  the rFIXFc 
injection. 
l Injection site inspection is to be performed after each injection of rFIXFc that the subject receives during  a site 
visit. 
m The subject/  parent/caregiver must enter  dosing information into the EPD as soon as possible after an injection 
and within a maximum of 7 days following the injection  (Section 10.1.2). It is recommended that 
subjects/parents/caregivers enter dosing information immediately after an injection.  
n Clinic dosing applicable only if warranted.  
o It is recommended that t he subjec t/parent/caregiver enter the response to a bleeding epi[INVESTIGATOR_71225] ( Section [IP_ADDRESS]). In addition  to scheduled clinic visits, telephone calls are planned 
approximately once a month for study site staff to check on each subject‚Äôs status.  During the monthly phone call, the 
subject‚Äôs parent/caregiver will also be reminded about the requirement for timely EPD data entry, and assessments of ‚Äúspontaneous‚Äù and ‚Äútraumatic‚Äù bleeds will be noted.  
p AEs and SAEs are to be monitored and recorded starting from the time of signing informed consent .  
q For subjects who are receiving breast milk, maternal concomitant medications will also be collected at the same 
time points as other concomitant therapi[INVESTIGATOR_014], unless the breast milk is derived from a source other than the mother or the mother has not consented.   
Note: Additional unscheduled visits may be necessary during t he study to test for inhibitors, test for recovery, repeat 
safety assessments, or repeat any blood sampling if required for study purposes or for local standard of care.   
 
 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
24 [IP_ADDRESS]. Schedule of Events:  Exposure Day Milestone Visits  
In addition to the assessments at the interim visits described in Section [IP_ADDRESS], subjects must 
undergo testing for inhibitors and anti -rFIXFc drug antibody at the ED milestones shown below. 
One ED is defined as a [ADDRESS_77476] the samples collected.   
 Visits at 
Activities  5 EDs  
(¬±2 EDs)  10 EDs  
(10 to 15 EDs) 20 EDs 
(20 to 25 EDs) 50 EDs  
(50 to 55 EDs) 
Nijmegen -Modified Bethesda 
Assay (Inhibitor Assay)a, b X X X X 
Anti-rFIXFc Antibodya X X X X 
F9 Genotypi[INVESTIGATOR_71226] = exposure day  
a Washout prior to sample collection for  the inhibitor and anti -rFIXFc antibody tests should be at least [ADDRESS_77477] result.  In addition , if inhibitor development is suspected at any 
time during the study (e.g., the expected plasma factor IX activity levels are not attained or if bleeding is not 
controlled with an expected dose), samples will be collected for inhibitor testing by [CONTACT_71335]-rFIXFc antibody testing.  
b If the subject‚Äôs genotype was not already known at Screening and the sample could not be drawn due to blood 
volume limitations at the Predose Baseline IR Visit, this assessment may be performed at any other visit.  If the 
subject develops an inhibitor on the study, a sample may be drawn for this testing at any time during the Treatment Period. The parent/legal guardian must provide separate consent for genotypi[INVESTIGATOR_007].  
 
 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
25 4.2.3. Schedule of Events:  Surgery Visits   
Tests and Assessments  Pre-Surgery 
(Week -4 to 
Week -2)a Preoperative 
Assessment/Day 
of Surgeryb Postoperative 
Visit (1 to 2 
weeks after  
surgery)c Last 
Postoperative 
Visitd 
Physical Examination  X X X  
Weight (kg)  X X X X 
Vital Signse X X X  
Hematologyf  Xg X X 
Blood Chemistryh  Xg X X 
FIX Activityi Xg Xg X X 
Nijmegen -Modified Bethesda 
Assay (Inhibitor Assay)j, k Xg Xg X X 
rFIXFc Dosingl X X X X 
Anti-rFIXFc Antibodyj, k Xg Xg X X 
EPD Review, including rFIXFc 
Dosing Accountabilitym X X X X 
Investigator/Surgeon ‚Äôs 
Assessment of Responsen  X X  
AE/SAE Monitoring and 
Recording  <<<<ONGOING:  Monitor and record at all visits>>>>  
Concomitant T herapy/ 
Procedure s Recording  <<<<ONGOING:  Monitor and record at all visits>>>>  
AE = adverse event; EOS = end of study; EPD = electronic patient diary; ET = early termination; FIX = coagulation 
factor IX; rFIXFc = recombinant coagulation factor IX Fc fusion protein; SAE = serious adverse event.  
a Not required for emergent surgery.  
b If surgery is delayed by ‚â•[ADDRESS_77478]‚Äôs parent/caregiver to determine when the subject should return to the regular pre-surgery 
regimen.  
c Visit is required for major surgeries only.   
d Visit is required for major surgeries only.  This visit occurs when the Investigator determines the subject can return 
to the regular pre-surgery regimen and is not required if the return to the regular pre -surgery regimen occurs at the 
Postoperative Visit (1 to 2 weeks after surgery).  If the subject  is withdrawn from the study, then he will complete  
ET/EOS Visit assessments (see Section [IP_ADDRESS]) at least 2 weeks after surgery.  
e Vital signs include temperature ( ¬∞C), blood pressure, pulse rate, and respi[INVESTIGATOR_697]. Postdose assessments 
following in -clinic injections should be taken approximately [ADDRESS_77479] of 
care.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
26 h Blood chemistry includes sodium, potassium, chloride, total protein, total bilirubin, gamma glutamyl transferase, 
aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, blood urea nitrogen, serum creatinine, 
and glucose.   
i Samples for determination of predose FIX activity levels will be co llected prior to the dose of rFIXFc, given for the 
surgery, and FIX activity levels  will be sampled 10 (¬±5) minutes after the end of the rFIXFc injection . For major 
surgeries, a  repeat blood draw for FIX activity should be taken approximately [ADDRESS_77480]/parent/caregiver enter 
the response to a bleeding epi[INVESTIGATOR_71227] ( Section [IP_ADDRESS]).   
n For minor surgeries, assessment  of response  is conducted on the day of surgery; for major surgeries, assessment 
occurs 24  hours after surgery and at the Postoperative Visit (1 to 2 weeks after surgery).  See Appendix  D. 
 
 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
27 4.2.4. Schedule of Events:  Immune Tolerance Induction Visits 
The following schedule applies to subjects who are eligible for ITI, as described in 
Section 10.2.6.  
Tests and Assessments  Pre-ITI 
Assessment  
(ITI 
Week 0) ITI: 
Week 4 
to Week 
24 
Visits 
every 
4 (¬±2) 
weeks ITI: 
Week 36 
to EOT 
Visits 
every 
12 (¬±2) 
weeks Once 
Confirmed 
Negative 
Inhibitor:  IR 
Assessments 
(add to an 
existing visit)a ET/EOS 
Visit for 
ITI Safety 
Follow-Up 
for ITIb 
Informed Consent  X      
Physical Examination  X X X  X  
Weight (kg)  X X X  X  
Vital Signsc X X X  X  
Hematologyd X Xe Xe  X  
Urinalysis  X X X  X  
Blood Chemistryf X Xg Xg  X  
Nijmegen -Modified 
Bethesda Assay 
(Inhibitor Assay)h,i X X X  
X  
rFIXFc Dosingj X X X X X  
FIX Activity  Xk Xk Xk X Xk  
Anti-rFIXFc Antibodyh, i X X X  X  
EPD Review, including 
rFIXFc Dosing 
Accountabilityl X X X  
X  
Injection Site Inspectionm X X X  X  
Adverse Events  <<<<ONGOING:  Monitor and record at all visits; telephone call every month >>>> 
Serious Adverse Events  <<<<ONGOING:  Monitor and record at all visits; telephone call every  month>>>> 
Concomitant Therapy/ 
Procedures Recordingn <<<<ONGOING:  Monitor and record at all visits; telephone call every month >>>> 
AE = adverse event; DHA=Directions for Handling and Administration; EOS = end of study; EPD = electronic 
patient diary; EOT = end of treatment; ET = early termination; FIX = coagulation factor  IX; ITI = immune tolerance 
induction; rFIXFc = recombinant coagulation factor IX Fc fusion protein; SAE = serious adverse event . 
a The incremental recovery ( IR) assessments will be pe rformed once subjects have achieved 2 consecutive negative 
inhibitor tests, and could occur at any time during ITI treatment  when these conditions are met ; the IR assessment 
will be added to an existing visit for ITI treatment.  Samples for IR assessments are to be taken when the subject is 
in a non-bleeding state, after at least a [ADDRESS_77481] be calculated using the actual potency as described in the DHA and in Section 10.1.1 of the 
protocol; the dose of rFIXFc for these IR assessments is 50 IU/kg.  Blood samples will be taken predose within 
30 minutes prior to the start of rFIXFc injection and postdose 10 (¬±5) minutes after the end of the rFIXFc 
injection.   
 For further details, see 
Section [IP_ADDRESS].  
b A follow-up telephone or in person visit is required 14 (+7) days after  the last dose of rFIX Fc to monitor AEs, 
SAEs, and concomitant medications and procedures . The 14-day follow -up is not required if subject s end their 
participation in this study to enroll into another rFIXFc study.  
c Vital signs include temperature ([¬∞C]) , blood pressure, pulse  rate, and respi[INVESTIGATOR_697]. Postdose assessments 
following in -clinic injections should be taken approximately [ADDRESS_77482] at the ET/EOS Visit is not evalu able.  
j Clinic dosing applicable only if warranted .  
k At discretion of Investigator.  Samples for FIX activity  will be taken if the subject is in a non -bleeding state, after at 
least a 72 -hour washout.  Blood samples will be taken predose within 30 minutes  prior to the start of rFIXFc 
injection and postdose 10 (¬±5) minutes after the end of the rFIXFc injection.   
l The subject/parent/caregiver must enter dosing information into the EPD as soon as possible after an injection and 
within a maximum of 7 days fol lowing the injection ( Section 10.1.2). It is recommended that 
subjects/parents/caregivers enter dosing information immediately after an injection.  
m Injection site inspection is to be performed after each injection of rFIXFc that the subject receives during  a site 
visit.  
n For subjects who are receiving breast milk, maternal concomitant medications will also be collected at the same 
timepoints as oth er concomitant therapi[INVESTIGATOR_014], unless the breast milk is derived from a source other than the mother or 
the mother has not consented.   
 
 

Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
29 5. INTRODUCTION 
In this study, previously untreated male subjects will receive recombinant coagulation factor IX 
Fc fusion protein (rFIXFc; BIIB029) according to local standard of care for implementation of a 
prophylaxis regimen, including an optional preceding epi[INVESTIGATOR_49564] (on -demand) treatment regimen . 
The European Medicines Agency (EMA) Committee for Medicinal Products for Huma n Use 
(CHMP) g uideline on c linical investigation of recombinant and human plasma -derived f actor IX 
products [EMA (EMA/CHMP/BPWP/144552/2009) 2011]  was followed in the development of 
this protocol.  
5.1. Profile of Previous Experience  
Hemophilia B (congenital coagulation factor IX [FIX] deficiency; Christmas disease) is an 
X-linked bleeding disorder that occurs predominantly in male s, characterized by a deficiency of 
functional FIX. Hemophilia A and B are estimated to affect 460,000 people worldwide, with hemophilia B representing approximately 20% of those cases [Skinner 2012] . Hemophilia is a 
serious, life- threatening disorder. Individuals with severe hemophilia experience frequent and 
recurrent spontaneous or traumatic bleedin g into the soft tissue s, body cavities, and joints, 
leading to arthropathy, muscle contractures, and severe disability. A severe complication is 
central nervous system bleeding, resulting in death or disability [Ljung 2008] . Intracranial 
hemorrhage is one of the leading causes of bleeding death in individuals with hemophilia [Witmer 2011] . From an epi[INVESTIGATOR_71228], severe hemophilia is defined as a FIX 
activity level of <1% ; for the purpose of clinical studie s, severe hemophilia is defined as a FIX 
activity level of ‚â§2% [Lambert 2007; Martinowitz 2012; Negrier 2011; Santagostino 2012] .  
5.1.1. Therapi[INVESTIGATOR_71229] B  
Clinical studies have led to the widespread adoption of prophylaxis as a m ajor advance in 
treating hemophilia [Manco-Johnson 2007; Nilsson 1992; Nilsson 1970] . While these studies 
were predominantly conducted in subjects with hemophilia A, prophylaxis is currently considered standard of care in the developed world and is recommended by [CONTACT_71336] U nited States  National Hemophilia Foundation‚Äôs Medical and Scientific 
Advisory Council for both hemophilia A and B. Epi[INVESTIGATOR_71230] a high  
frequency of bleeding epi[INVESTIGATOR_1841], which vary in reported literature but can be approximately 20 bleeding epi[INVESTIGATOR_11114], whereas patients with hemophilia B who are treated 
prophylactically are reported to experience as few as 3 to 4 spontaneous bleeding epi[INVESTIGATOR_71231] [Lambert 2007; Monahan 2010; Shapi[INVESTIGATOR_2152] 2005] . Annual bleeding rates tend to be lower in 
children on primary prophylaxis [Manco -Johnson 2007]  compared with older children or adults 
on secondary prophylaxis, who have joint damage that predisposes them to higher annual bleeding rates.   
There is no currently available cure for hemophilia B.  While innovations such as gene therapy 
are in development, current treatment focuses on factor replacement therapy with plasma-derived 
factor IX ( pdFIX) or recombinant coagulation factor IX ( rFIX) products. Current ly available 
pdFIX and rFIX have similar efficacy and safety profiles.  The rFIX concentrate, BeneFIX
¬Æ, is 
not associated with the theoretical risk of blood-borne pathogen transmission [BeneFIX¬Æ 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
30 Prescribing Information 2011] . A limitation of rFIX is its short elimination half -life (t¬Ω), with a 
mean of 18 to 22 hours and variably lower in vivo recovery compared with pdFIX products 
[BeneFIX¬Æ Prescribing Information 2011; Lambert 2007; Roth 2001] .  
5.1.2. rFIXFc 
rFIXFc is a fully recombinant fusion protein consisting of a single molecule of human FIX 
covalently linked to the dimeric Fc domain of human immunoglobulin G1 (IgG1) with no 
intervening sequence.  This type of construct has been termed a monomeric Fc f usion protein 
[Dumont 2006] .  
While the FIX moiety  of rFIXFc retains FIX coagulation activity, the Fc component of rFIXFc 
binds with neonatal Fc receptor (FcRn), which is expressed on many adult cell types. The Fc 
domain is responsible for the long circulating t ¬Ω of IgG1 through interaction with the FcRn 
[Roopenian and Akilesh 2007] . The same naturally occurring pathwa y similarly delays 
lysosomal degradation of immunoglobulins by [CONTACT_71337] t
¬Ω. rFIXFc is being developed as a treatment for hemophilia B 
that would have a longer circulating t ¬Ω while maintaining the activity profile of FIX.   
5.1.3. Summary of Preclinical Experience With rFIXFc  
rFIXFc was evaluated in a comprehensive nonclinical program, which included pharmacokinetic (PK), pharmacology, and toxicology studies. The results of the nonclinical program provided the following critical results: 
‚Ä¢ Improved PK parameters (e.g., increased elimination t
¬Ω) were observed for rFIXFc in 
several animal species, and administered rFIXFc retained its functional activity while present in the circulati on.  
‚Ä¢ Prolonged pharmacodynamics and efficacy were observed for rFIXFc in several 
animal species.   
‚Ä¢ Similar potency was found for rFIXFc and BeneFIX in an acute bleeding model.  
‚Ä¢ The toxicology program established that rFIXFc was well  tolerated in 3 different 
species (rats, monkeys, and rabbits).  
‚Ä¢ The safety margin is [ADDRESS_77483] 
levels (1000 international units [ IU]/kg) with the highest routine dose of 100 IU/kg 
used in clinical studies.   
For further details reg arding the preclinical studies conducted with rFIXFc, refer to the rFIXFc 
Investigator‚Äôs Brochure.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
31 5.1.4. Summary of Clinical Experience With rFIXFc  
Three clinical studies, a Phase 1/2a study (S tudy SYN-FIXFc-07-001) and 2 Phase 3 studies  
(Study 998HB102 and 9HB02PED), have been completed. Two additional clinical studies, an 
extension study ( Study 9HB01EXT ) and this study in previously untreated patients or PUPs 
(Study 998HB303), are ongoing.  
In the open -label, multicenter Phase 1/2a study ( Study SYN-FIXFc-07-001), 14 previously 
treated patients ( PTPs) ‚â•18 years of age with severe hemophilia B (defined as ‚â§2 IU/dL [‚â§2%] 
endogenous FIX) received a single injection  of rFIXFc in escalating doses at 6  dose levels (1, 5, 
12.5, 25, 50, and 100 IU/kg) and were evaluat ed for safety and PK.  A single dose of rFIXFc was 
well tolerated at all dose levels administered in this study.  None of the subjects developed 
inhibitors and there were no reports of drug- related serious adverse events ( SAEs). Dose-linear 
PK of rFIXFc was demonstrated in the dose range of 12.5 to 100 IU/kg.  
The Phase 3 study in adults and adolescents (Study 998HB102) was an open- label, multicenter 
study that evaluated the safety, PK, and efficacy of rFIXFc in 123 PTPs with severe 
hemophilia B (defined as ‚â§2 IU/dL [‚â§2%] endogenous FIX) ‚â•[ADDRESS_77484]. The measured t¬Ω of rFIXFc was 82 hours, which is 2.43-fold 
longer than observed for BeneFIX (rFIX).  rFIXFc was effective in the control of bleeding with 
>90% acute bleed ing epi[INVESTIGATOR_1865] s controlled with a single injection.  rFIXFc was effective in each of 
2 routine prophylaxis regimens with >80% reduction in annualized bleeding rate (ABR) relative 
to epi[INVESTIGATOR_71232].  The median weekly dose during the last 6 months on study in the weekly 
prophylaxis arm was 40.7 IU/kg. The median dosing interval during the last 6 months on study in 
the individualized interval prophylaxis arm (dosed at 100 IU/kg) was 13.8 days.  rFIXFc was 
effective when used for perioperative managem ent, with 100% of major surgeries having 
excellent or good hemostasis.   
The safety  data from Study 998HB102 includes 12 3 subjects  aged 12 years and older with severe 
hemophilia B, with 59 subjects having ‚â•50 EDs. Overall, the adverse event ( AE) profile was  
generally consistent with that expected in patients with hemophilia B.  No inhibitor development 
was observed in this clinical study. There were no severe allergic reactions or vascular 
thrombotic events. Adverse drug reactions (ADRs) were defined as AEs assessed by [CONTACT_71338]. The most common  ADRs observed in the Phase 3 adult and adolescent study (incidence 
>1%) were headache and oral paresthesia.  One serious ADR  of obstructive uropathy was 
reported in a subject with hematuria who developed an obstructing clot in the urinary collecting system. The event resolved with hydration, and the subject continued prophylactic treatment with 
rFIXFc. The safety of rFIXFc was consistent across the patient  population evaluated and there 
were no meaningful differences in safety profile by [CONTACT_654], race, geography, body mass index, or co-morbidities such as hepatitis C virus or human immunodeficiency virus (HIV) .  
Phase 3 study 9HB02PED was an open- label, multicenter study of pediatric PTPs in which 30 
subjects aged <[ADDRESS_77485] of age on PK of coagulation factors, there appeared to be a decrease in incremental recovery (IR) and an increase in clearance in pediatric patients <12 years of age compared with 
adults and adolescents ( Table 1). rFIXFc was also observed to have a prolonged t
¬Ω and reduced 
clearance compared with other FIX products, consistent with results for subjects 12 years and 
older.  
Phase 3 study 9HB01EXT is an ongoing open- label, multicenter extension study of the long -term 
safety and efficacy of rFIXFc in PTPs who completed other studies such as Study 998HB102 
and 9HB02PED. As of 17 October 2014, the type and incidence of AEs observed in the study 
were generally similar to what is expected for the general adult and pediatric hemophilia 
population. The results from this study as of that date suggested that, in line with the parent 
studies (Studies 998HB102 and 9HB02PED), rFIXFc treatment during the extension study was  
well tolerated and effective for the prevention and treatment of bleeding and for routine 
prophylaxis using either a weekly regimen, an individualized regimen with injections 
approximately every 2 weeks, or a personalized regimen. Surgical data from 15 major surgeries in 8 subjects confirmed the efficacy of rFIXFc for perioperative management in major surgery. 
For further details regarding the clinical studies conducted with rFIXFc, and for descriptions of 
the potential risks and benefits of rFIXFc, refer to the rFIXFc Investigator‚Äôs Brochure.  
 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ Therapeutics Inc  
33 Table 1: Comparison of rFIXFc  PK Parameters by [CONTACT_71329]: G eometric Mean (95 % Confidence Interval [ CI]) 
 
Source: rFIXFc Investigator‚Äôs Brochure, V10.0, Table [ADDRESS_77486] of care in hemophilia due to the demonstrated 
benefit on long- term outcomes [Aznar 2000; Manco-Johnson 2007; Molho 2000] . Currently 
available FIX replacement therapi[INVESTIGATOR_71233] t ¬Ω requiring intravenous (IV) 
administration up to 3 times per week.  
The purpose of this study is to investigate the safety and efficacy of rFIXFc in previously 
untreated patients (PUPs) in accordance with the EMA CHMP guideline on clinical investigation 
of recombinant and human plasma-derived factor IX products [EMA 
(EMA/CHMP/BPWP/144552/2009) 2011] .  
5.3. Rationale for Dose and Schedule Selection 
Results of the Phase 1/2a study ( Study SYN-FIXFc-07-001) evaluating the safety and PK of a 
single dose of rFIXFc suggested that rFIXFc is well tolerated when given as a single dose at doses ranging from 1 to 100 IU/kg. In the completed Phase 3 study ( Study 998HB102), multiple 
doses between 20 and 100 IU/kg were generally well tolerated, with an AE profile generally 
consistent with that expected in patients with hemophilia B.  No dose- limiting toxicity (DLT) has 
been identified to date in humans receiving a dose of rFIXFc up to 100 IU/kg. 
The recommended starting prophylactic dose of rFIXFc in this study, approximately 50 IU/kg 
weekly, is based on the data from the Phase 1/2a and Phase 3 studies (including pediatric PK 
data from s ubjects <12 years of age) and knowledge of increased clearance of factor concentrates 
in children ( Table 1). This dose is predicted to maintain trough levels >1% in 99% of pediatric 
subjects. Adjustments to the dose and interval of rFIXFc can be made in this study based on 
available PK data, subsequent FIX activity levels, level of physical activity, and bleeding  pattern, 
in accordance with local standards of care for a prophylactic regimen.   
The dose for treatment of bleeding epi[INVESTIGATOR_71234] 30% to 100%, in accordance with local standards (see guidance provided in 
Appendix A ), and taking into account lower rFIXFc recoveries o bserved in young children 
(Table 1). Subjects developi[INVESTIGATOR_71235] (see Section [IP_ADDRESS]).   
If a subject requires surgery while participating in this study, the  subject may be treated with the 
dose and regimen of rFIXFc deemed appropriate for the type of surgery. All major surgeries will 
be reported as serious adverse events ( SAEs).  
5.4. Potential Risks and Benefits  
Refer to the current Investigator‚Äôs Brochure for descriptions of the potential risks and benefits of 
rFIXFc.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
35 6. STUDY OBJECTIVES AND ENDPOINTS  
6.1. Objectives 
6.1.1. Primary Objective  
The primary objective of the study is to evaluate the safety of rFIXFc in previously untreated 
subjects with severe hemophilia B.   
6.1.2. Secondary Objectives  
The secondary objectives of the study are as follows: 
‚Ä¢ To evaluate the efficacy of rFIXFc in the prevention and treatment of bleeding 
epi[INVESTIGATOR_71201] .  
‚Ä¢ To evaluate rFIXFc consumption for prevention and treatment of bleeding epi[INVESTIGATOR_71200].  
6.1.3. Exploratory Objectives  
The exploratory objective of the study i s to evaluate the effect of rFIXFc based on 
patient-reported outcomes and health resource utilization.  
6.2. Endpoints  
6.2.1. Primary Endpoint  
The primary endpoint of the study is the occurrence of inhibitor development.  
6.2.2. Secondary Endpoints  
The secondary endpoints of the study are as follows:  
‚Ä¢ the annualized number of bleeding epi[INVESTIGATOR_1841] (spontaneous and traumatic) per subject 
‚Ä¢ the annualized number of spontaneous joint bleeding epi[INVESTIGATOR_71202] 
‚Ä¢ assessments of response to treatment with rFIXFc for bleeding epi[INVESTIGATOR_1841], using the 
4-point bleeding response scale (Investigator assessment for bleeding epi[INVESTIGATOR_71236]; parent or caregiver assessment for  all other bleeding epi[INVESTIGATOR_1841]) 
‚Ä¢ the total number of EDs  per subject per year  
‚Ä¢ total annualized rFIXFc consumption per subject for the prevention and treatment of 
bleeding epi[INVESTIGATOR_71237] 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
36 ‚Ä¢ the number of injections and dose per injection of rFIXFc required to resolve a 
bleeding epi[INVESTIGATOR_1865]  
‚Ä¢ rFIXFc incremental recovery   
6.2.3. Exploratory Endpoints  
The exploratory endpoints include, but are not limited to : 
‚Ä¢ health outcomes  
Protocol 998HB303  Version [ADDRESS_77487] Screening Visit and the confirmation of eligibility.  Following 
the confirmation of eligibility, administration of commercially available rFIXFc is no longer 
allowed and only rFIXFc labeled for study use is to be administered (henceforth, the latter  supply 
will be described as rFIXFc study drug , to distinguish it from commercially available rFIXFc) . 
Subjects with a documented plasma F IX activity of ‚â§2% may be enrolled on the basis of local 
laboratory results and may receive study drug after samples for factor IX activity level and 
inhibitors have been obtained for testing at the central laboratory.  However, any such subject 
must be withdrawn if the central laboratory screening results indicate factor IX activity level 
>2% or a positive inhibitor. Baseline incremental recovery ( IR) assessments described in  
Section 4.2.[ADDRESS_77488] epi[INVESTIGATOR_71238] ( on-demand) prior to initiating a prophylaxis regimen.  The duration of 
epi[INVESTIGATOR_71205]‚Äôs discretion, in accordance with local standard of care.  
At least [ADDRESS_77489] injection of rFIXFc defined as the start of the 
ED.  
Surgery is allowed during the study. See Section  10.2.7 for further instructions.  
Immune tolerance induction (ITI) with rFIXFc  is allowed during the study for those subjects 
developi[INVESTIGATOR_007], after exposure to rFIXFc study drug, a positive low titer inhibitor (‚â•0.60 and 
<5.00 Bethesda unit [BU] /mL) with bleeding epi[INVESTIGATOR_71239], or a positive high titer inhibitor (‚â•5.00 BU/mL). See Section  10.2.[ADDRESS_77490] administration of rFIXFc 
(commercially available rFIXFc and/or study drug) must be performed  under medical 
observation where proper medical care for allergic reactions could be prov ided. The first 
injection of rFIXFc study drug after the confirmation of eligibility  must be administered by [CONTACT_71339] a qualified delegate.  Thereafter, study drug may be administered by a 
parent/caregiver, a qualified medical professio nal under the direction of the Investigator, 
self-administered by [CONTACT_71340], or given at the clinic. Study treatment may also be injected 
in the hospi[INVESTIGATOR_307] , for example,  during surgery or during hospi[INVESTIGATOR_71240].  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
38 See Figure 1  for a schematic of the study design  and Section 4.2 for a description of each study 
visit and the required assessments . Section 10 describes the treatment of subjects during the 
study.  
7.2. Study Specifics  
7.2.1. Dose-Limiting Toxicity  
No DLT has been identified to date in humans receiving doses of rFIXFc up to 100 IU/kg. Also, 
no DLTs were observed in the preclinical animal studies where repeat doses of up to 1000 IU/kg 
were evaluated . The dose for treatment of bleeding epi[INVESTIGATOR_71241] 30% to 100%, in accordance with local standards (see guidance provided in 
Appendix A ), and taking into account lower r FIXFc recoveries observed in young children 
(Table 1).  
7.3. Overall Study Duration and F ollow-Up 
The study period will consist of screening, treatment, and follow-up. Individual subject study 
participation is expected to be approximately [ADDRESS_77491] 50 EDs to the study treatment, unless withdrawal from the study occurs, or the 
end of study is declared . EDs are defined as in Section  7.1.  
See Figure 1 for a schematic of the study design.  
7.3.1. Screening  and Baseline Incremental Recovery Visits  
Parents/legal guardians of subjects must be provided with the informed consent information prior 
to the Screening Visit to allow adequate time for review and an opportunity to discuss the study 
with the Investigator/designee. After reviewing, parents/legal guardians and subjects will come 
into the clinic to sign the informed consent/assent; then subjects will undergo screening.  
Screening assessments to determine s ubject eligibility for the study will be collected within 
[ADDRESS_77492] Screening Visit (i.e., the first visit for any activity other than informed 
consent, which can occur prior to the subject‚Äôs birth), see Section  4.2.1. As  part of the screening 
process, the Investigator must have sufficient documentation of a subject‚Äôs medical history to 
ensure previously untreated status.  
If more than [ADDRESS_77493] be completed within an additional 8 weeks. 
Potential subjects may be enrolled and receive study drug as long as they meet the minimum 
criteria for enrollment ( Section 8.3), including factor IX activity ‚â§2% from the local labor atory 
(either at Screening or documented in the medical record ) and collection of samples for inhibitor 
and factor IX activity testing at the central laboratory . If results from  central laboratory testing of 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
39 the screening samples for inhibitor and factor IX activity  subsequently reveal a factor  IX activity 
level >2% or a positive inhibitor, the subject must be withdrawn. 
The Baseline IR Visit assessments should be performed as soon as practicable once all eligibility 
criteria have been met  and the subject has been enrolled . The Baseline IR Visit activities 
(Section 4.2.1) may be completed on the same day as Screening, or they may be co mpleted as 
part of a separate visit or at an unscheduled visit. Baseline IR assessments must be performed 
when the subject is in a non-bleeding state, after at least a 72 hour washout. Eligible subjects will 
report to the study site for administration in the clinic of  the Baseline IR Visit dose of 50 IU/kg 
by [CONTACT_71341] (see the Directions for Handling and Administration [ DHA] and Section 10.1.1 
of this protocol for further information on actual potency dosing). The dose will be delivered via a slow push IV injection over several minutes, at a rate of administration determined by [CONTACT_1560]'s comfort level . Subjects will be required to complete the assessments according to 
Section 4.2.1, including collection of FIX  activity samples for the calculation of incremental 
recovery.  
Bleeding epi[INVESTIGATOR_71242]. If a subject requires more than [ADDRESS_77494] with an epi[INVESTIGATOR_71243] a period of time before initiating a prophylaxis regime n. 
The duration of the epi[INVESTIGATOR_71244] I nvestigator‚Äôs discretion, in accordance with local 
standard of care.  However, given global standards of care, it is expected that the prophylactic 
regimen will be initiated prior to or immediately following  a third epi[INVESTIGATOR_71245]. 
The date of transition from epi[INVESTIGATOR_71246] a prophylaxis regimen must be captured on the 
electronic case report form (eCRF).  The recommended starting prophylactic regimen is 50 IU/kg 
weekly, although adjustments to the dose and dosing interval of rFIXFc can be made based on 
available PK data, subsequent FIX activity levels, level of physical activity, and bleeding pattern, 
in accordance with local standards of care for a prophylactic regimen.  Treatment will continue 
until the subject has reached at least 50 EDs to rFIXFc.  Parents/c aregivers, or children capable of 
self-injection, will be instructed on how to administer  rFIXFc at home.   
Following confirmation of eligibility and enrollment, subjects will report to the s tudy site for 
2 kinds of required visits during the Treatment Period: 
‚Ä¢ Scheduled Interim Visits: every 12 (¬±2) weeks after enrollment,  by [CONTACT_1580] 
(Section [IP_ADDRESS]).  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
40 ‚Ä¢ ED Milestone Visits: at 5 (¬±2) EDs, 10 to 15 EDs, 20 to 25 EDs, and 50 to 55 EDs 
(Section [IP_ADDRESS]). 
In addition to scheduled clinic visits , telephone calls with the subject‚Äôs parents/caregivers are 
planned approximately once a month for study site staff to check on each subject‚Äôs status.  
Additional unscheduled visits may be necessary during the study to test for inhibitors, test for 
recovery, repeat safety assessments, repeat any blood sampling if required for study purposes or for local standard of care, or perform PK assessments if needed for surgical planning or 
adjustment of dosing regimen.  Investigators are to report all inhibitor assessments performed 
throughout the study on the eCRF.  
Subjects who develop inhibitors may be eligible for 24 months of Immune Tolerance Induction 
Therapy (ITI)  (Section 4.2.4 and Section  10.2.6).  
7.3.3. Post-Treatment  Follow-Up 
Subjects will perform the assessments of the Early Termination (ET)/End of Study (EOS) Visit after at least [ADDRESS_77495] withdrawn from the study, or the 
end of study is declared . A Final Safety Follow -up Visit/Telephone Call will be conducted 14 
(+7) days  after the last dose of rFIXFc to assess the subject‚Äôs status  for AEs, SAEs, and 
concomitant treatments and procedures. It will be at the discretion of the Investigator to conduct 
the Final S afety Follow-up Visit by [CONTACT_52062].  
7.4. Study Stoppi[INVESTIGATOR_71247], after informing Investigators.  Investigators will 
be notified by [CONTACT_71342], stopped, or closed.  
Study stoppi[INVESTIGATOR_71211] : 
‚Ä¢ unacceptable inhibitor incidence as determined by [CONTACT_71343] (DSMC; see Section 19.2) 
‚Ä¢ detection of an unexpected, serious, or unacceptable risk to the study subjects 
Data regarding frequency of inhibitor development will be reviewed by [CONTACT_71344]. If, after consideration of subject-specific risk factors (e.g., genotype), the DSMC 
judges that the observed rate of inhibitor formation is unacceptable, compared with that reported 
for commercially available rFIX concentrates, the study will be stopped.   
If the study is stopped, the events will be investigated, enrollment will be stopped, and current 
subjects will stop dosing with rFIXFc.  If, in consultation with the DSMC, it is determined that 
the study should be permanently discontinued, then subjects wil l attend a final visit.   
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
41 7.5. End of Study  
The end of the study (EOS) will occur when at least [ADDRESS_77496] 50 EDs 
with rFIXFc.  Once this milestone  has been achieved , all ongoing study subjects will be required 
to return to the study center for the Early Termination (E T)/End of Study ( EOS) Visit 
assessments.   
The end of treatment for individual subjects is described in Section  10.6. 
  
  
Protocol 998HB303  Version [ADDRESS_77497] meet the following eligibility criteria 
at the time of screening, or at the timepoint specified in the individual eligibility criterion listed: 
1. Ability of the subject or the subject‚Äôs legally authorized representative (e.g., their parent 
or legal guardian ) to understand the purpose and risks of the study and provide signed 
and dated informed consent and authorization to use confidential health information , 
and/or to provide assent, in accordance with national and local subject privacy 
regulations.  
2. Male, age <18 years at the time of informed consent.  
3. Weight ‚â•3.5 kg.   
4. Severe hemoph ilia B defined as ‚â§2 IU/dL (‚â§2%) endogenous FIX documented with local 
laboratory results either  in the medical record  or as tested during the Screening P eriod. 
Any subject who is enrolled based on results of the local laboratory (from the medical 
record or at screening) must be withdraw n if the central laboratory screening results 
indicate a baseline FIX activity level >2% of normal.   
8.2. Exclusion Criteria  
Candidates will be excluded from study entry if any of the followi ng exclusion criteria exist at 
Screening, or at the timepoint specified in the individual criterion listed: 
1. History of positive inhibitor testing . A prior history of inhibitors is defined based on a 
patient's historical positive inhibitor test using the local laboratory Bethesda value for a 
positive inhibitor test (i.e., equal to or above lower limit of detection).   
2. History of hypersensitivity reactions associated with any rFIXFc administration.   
3. Exposure to blood components or i njection with a FIX concentrate (including plasma 
derived) other than rFIXFc.  
4. Injection with commercially available rFIXFc more than 28 days prior to Screening.  
5. More than 3 injections of commercially available rFIXFc prior to confirmation of 
eligibility .  
6. Other coagulation disorder(s) in addition to hemophilia B.   
7. Any concurrent clinically significant major disease that, in the opi[INVESTIGATOR_689], would make the subject unsuitable for enrollment (e.g. , HIV infection with 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
43 CD4 lymphocyte count <200 cells/ ŒºL or a viral load >200 particles/¬µL, or any other 
known congenital or acquired immunodeficiency).  
8. Current systemic treatment with chemotherapy and/or other immunosuppressant drugs. 
Use of steroids for treatment of asthma or management of acute allergic epi[INVESTIGATOR_71248] -threatening epi[INVESTIGATOR_71249] . Treatment in these circumstances should 
not exceed a [ADDRESS_77498] been met:  
‚Ä¢ Diagnosis of severe hemophilia B with factor IX activity ‚â§2% has been documented 
by [CONTACT_12082]. 
‚àí Local laboratory data already present in the medical record are acceptable.  
‚Ä¢ Samples have been drawn for central lab oratory testing  for inhibitors and factor IX 
activity. 
‚àí The results are not required at the time of enrollment.   
‚àí If the results from  central laboratory testing of the screening sampl e subsequently 
reveal a factor  IX activity level >2% or a positive inhibitor, the subject will 
discontinue treatment and be withdrawn per Section  11. 
‚Ä¢ The individual has met the remaining eligibility criteria described in the inclusion and 
exclusion criteria (Section  8.1 and Section  8.2), including the lack of exposure to 
blood components and factor IX replacement products prior to enrollment.  
Protocol 998HB303  Version [ADDRESS_77499] and/or subject's legally authorized representative (e.g., parent or legal guardian), 
must be provided with the informed consent/assent document(s) prior to the Screening Visit to allow adequate time for review and an opportunity to discuss the study with the 
Investigator/designee.  After reviewing, parents/legal guardians , and subject if applicable, will 
come into the clinic to sign the informed consent/assent. 
Subjects (where applicable) , and/or parents/legal guardians, must provide consent/assent before 
any screening assessments are performed (Section 17.3).  
Subjects will be assigned a unique identification number as soon as informed consent has been 
obtained or at the Screening Visit. A centralized Interactive Voice/Web Response System 
(IXRS; see Section 19.1.2) will assign a unique 6- digit subject identification number to each 
subject. The unique number consists of the 3-digit site number (e.g., 105) and a sequential 3- digit 
subject number (e.g., 004). This number will be assigned regardless of whether the subject will 
be eligible for enrollment and subsequent treatment or not and will remain with the subject as the 
study-specific subject identifier.  Any subject identification numbers that are assigned will n ot be 
reused even if the subject does not receive treatment. The study site is responsible for 
maintaining a current log of subject number assignments in order to avoid assignment errors, 
such as duplicating or skippi[INVESTIGATOR_71250]. If a subject is excluded fr om the study, the reasons for 
exclusion will be documented in the subject‚Äôs source documents and on the screening log. The 
subject‚Äôs unique identification number must be entered on all study documentation (i.e., sample 
containers, drug accountability logs, source documents, etc).  As confirmation, the IXRS will 
provide the Investigator with written verification of the allocation of subject identification 
number by [CONTACT_71345].   
Refer to the Study Reference Manual for the IXRS User Manual .  
9.1.1. Screening Assessments  
Screening assessments should be completed within a total of [ADDRESS_77500] Screening 
Visit (i.e., the first visit for any activity other than informed consent, which can occur prior to the 
subject‚Äôs birth ) (Section  4.2.1). If more than [ADDRESS_77501] has not been 
enrolled in the study, some screening assessments will need to be repeated (see Section  7.3.1). 
As part of the screening process, the Investigator must have sufficient documentation of a 
subject‚Äôs medical history to ensure previously unt reated status.   
Subjects weighing <[ADDRESS_77502] document the rationale ( Section 14.6).  
Protocol 998HB303  Version [ADDRESS_77503] can be enrolled and begin treatment  with rFIXFc study drug. If results from  central 
laboratory testing of the screening laboratory sample subsequently reveal factor IX activity level 
>2% or a positive inhibitor, the subject will discontinue treatment and be withdrawn per Section 11. 
Participating study sites are required to document all screened candidates initially considered for inclusion in this study. If a subject is excluded from the study, the reasons for exclusion will be documented in the subject‚Äôs source documents and on the screening log. 
9.1.2. Bleeding Epi[INVESTIGATOR_71251] a subje ct sustains a bleeding epi[INVESTIGATOR_71252], the subject‚Äôs parent/legal guardian should contact [CONTACT_29261].  
Bleeding epi[INVESTIGATOR_71253] [ADDRESS_77504] has met all eligibility  criteria should be treated 
with rFIXFc study drug.   
9.1.3. Enrollment of Subjects  
Subjects will be considered enrolled when  the Investigator has verified that they are eligible 
according to the criteria in Sections  8.1 and 8.2 (see Section  9.1.1). Using the IXRS, the status of 
the subject should be updated to indicate the enrollment prior to dispensing rFIXFc study drug to 
the subject .  
As confirmation, the IXRS will provide the Investigator with written verification of the subject‚Äôs 
enrollment by [CONTACT_71345].   
After confirmation of eligibility and enrollment, the subject should be treated only with rFIXFc 
study drug . Subjects  treated with another FIX concentrate must permanently discontinue study 
treatment and be withdrawn from the study, although exceptions are allowed for 1 emergency or 
accidental use (Secti on 11). 
Subjects or their parent/caregiver must be issued with an electronic patient diary ( EPD) once 
eligibility has been confirmed and the  subject has been enrolled  (see Section 10.1.2 for further 
details regarding information to be recorded into the EPD).  
9.1.4. Baseline Incremental Recovery 
Baseline IR assessments described in Section 4.2.[ADDRESS_77505] containing FIX (including commercially available rFIXFc or a blood 
product transfusion) prior to  the dose f or the baseline IR assessment.   
For the Baseline IR measurement, a dose of 50 IU/kg will be given in the clinic as an IV 
injection. The actual potency of rFIXFc must be used to calculate the units and volume of 
rFIXFc infused for the Baseline IR Visit dose (see the DHA and  Section 10.1.1 of this protocol ).  
For the baseline IR assessment, b lood samples will be taken predose within 30 minutes prior to 
the start of the injection and postdose at 10 (¬±5) minutes after the end of the rFIXFc injection for 
assessment of IR, measured by [CONTACT_71346]- stage aPTT clotting assay.  According to the local 
standard of care, an IV access device may be offered to facilitate sample collection.  The IV 
access device must not be flushed with heparin between injection of rFIXFc and the collection of the samples.   
9.2. Registration  of Subjects  
At the Screening Visit, an IXRS will be used to assign each subject a unique 6- digit subject 
identification number (Section 9.1).   
Refer to the Study Reference Manual for details of registration.   
9.3. Blinding Procedures  
Not applic able. This is an open- label study.   
Protocol 998HB303  Version [ADDRESS_77506] for inhibitors, repeat safety 
assessments, repeat any blood samplin g if required for study purposes, or perform PK 
assessments if needed for surgical planning or adjustment of dosing regimen. Investigators are to 
report all visit assessments  performed throughout the study on the eCRF.  
Subjects requiring surgery will also  be followed via specialized visits ( Section 4.2.3). 
Instructions for preparation and administration of rFIXFc are provided in the DHA and the Information for Patients.  Dosing will be calculated as in the DHA and  summarized in 
Section 10.1.[ADDRESS_77507]‚Äôs comfort level.  Any missed doses should be taken as 
soon as possible or according to the instructions of the Investigator. 
Because of the risk of allergic reactions with FIX concentrates, the first administration of rFIXFc  
(commercially available rFIXFc and/or study drug) must be performed  under medical 
observation where proper medical care for allergic reactions could be provided. The first 
injection of rFIXFc study dr ug after the confirmation of eligibility must be administered by [CONTACT_71339] a qualified delegate.  Subjects and pa rents/caregivers will be instructed to 
administer subsequent rF IXFc doses at home, or to have them  administered by a qualified 
medical professional under the direction of the Investigator  or at the clinic .  
Treatment will continue until the subject has reached at least 50 EDs to rFIXFc, discontinues, 
completes ITI, or the end of study is declared. The end of the study for all subj ects is described 
in Section  7.5. 
10.1.1. Dosing Based on Actual Potency  or Nominal Strength  
This section explains when the actual potency or nominal strength is to be used for dose 
calculations.  The definitions of these terms and the types of dose calculations in this study are 
described below.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
48 Definitions  
‚Ä¢ The nominal strength is the target potency of the vial (that is, 250 IU, 500 IU, 
1000 IU, or 2000 IU per vial).  
‚Ä¢ The actual potency  is the true potency of the vial as measured by a validated potency 
assay. (Actual potency may vary between 80 % to 125% of nominal strength.)  
Calculation and Recording of Actual and  Nominal Dos es 
Actual potency must be used for dose calculations for the following: 
‚Ä¢ Dosing with partial vials (A ctual Potency dosing) , including the dose used for the 
calculation of Baseline IR , the dose used for IR assessments during ITI, and any 
other doses where the Investigator decides to use a partial vial. The actual potency 
shown on the vial must be used to calculate the units of rFIXFc and the volume to 
inject. Actual potency dosing is required for the dose of 50 IU/kg that is used to 
measure Baseline IR.  
Note: The instructions and worksheets provided in the DHA manual must be used to calculate 
the volume for administration based on actual potency . The actual potency shown on the vial 
must be used to calculate the volume for administration.  
Nominal strength must be used  for dose calculations for the following: 
‚Ä¢ Dosing with whole vials, including dos es used for prophylactic treatment , 
treatment of bleeding epi[INVESTIGATOR_1841], surgery , and the assessment of  FIX activity at 
interim visits . The nominal strength must be used for calculations.  Whole vials will 
be used to achieve the target dose, rounded as described in the DHA manual . These 
calculations should be discussed with the parent/caregiver  during regular monthly 
phone calls.  
Note: The instructions and worksheets provided in the DHA manual must be used to calculate 
the number of vials for administration based on nominal strength (unless an equivalent 
alternative site -specific template is approved by [CONTACT_71347]).  
10.1.2. Information to be Recorded for Treatment  
All rFIXFc injections administered during a study site visit must be recorded in the eCRF.  An 
injection administered during a site  visit must not be recorded in the EPD. Injections cannot be 
logged in both places. All injections performed while the subject is in the hospi[INVESTIGATOR_71254], including doses for surgery , must be recorded in the eCRF.  
All rFIXFc injections administered at home by [CONTACT_71348]/caregiver  or at locations 
other than the study site must be entered into the EPD. 
Protocol 998HB303  Version [ADDRESS_77508]‚Äôs parent/caregiver must enter dosing information into the EPD as soon 
as possible after an injection and within a maximum of 7 days following the injection , to 
ensure data integrity, and to facilitate appropriate medical review and dosing guidance.  It is 
recommended that subjects or parents/caregivers enter dosing information immediately after an injection. 
The study sites  and Clinical Monitors will ensure that there is consistency in dosing information 
between the subject‚Äôs medical record, IXRS, source documents, EPD, and eCRFs.  
10.2. Treatment  
10.2.1. Interim Visits  
10.2.2. Assessment of FIX  Activity During Interim Visits  
If an injection is administered during an Interim Visit while a subject is on a prophylactic dosing 
regimen, predose and post dose samples will also be taken to assess the need for a possible dose 
adjustment. Samples should be taken when t he subject is in a non- bleeding state  and after at least 
a [ADDRESS_77509]‚Äôs current prophylactic dose of rFIXFc may be used f or FIX activity assessments at 
Interim Visits. (For additional details  on dosing , see the DHA, as well as Section  10.1.1 of this 
protocol).  
rFIXFc will be delivered via a slow push IV injection over several minutes, at a rate of 
administration determined by [CONTACT_423]‚Äôs comfort level.   
Blood samples will be taken predose within 30 minutes prior to the start of the injection and 
postdose 10 (¬±5) minutes after the end of the rFIXFc injection , measured by [CONTACT_71346]- stage aPTT 
clotting assay.  According to the local standard of care, an IV access device may be offered to 
facilitate sample collection.  The IV access device must not be flushed with heparin between 
injection of rF IXFc and the collection of the samples.  
Assessment of FIX activity during ITI is discussed  separately in  Section [IP_ADDRESS]. 
[IP_ADDRESS]. Epi[INVESTIGATOR_71197] (Optional)  
Once eligibility has been confirmed and the subject has been enrolled, t he Investigator has the 
option to treat the subject epi[INVESTIGATOR_71238], until a p rophylactic regimen is initiated . Dosing will be 
determined by [CONTACT_71349] A  as a guideline.  The duration of epi[INVESTIGATOR_71255]‚Äôs discretion and should be based upon the Investigator‚Äôs treatment 
plan for the subject in accordance with the local standard  of care. However, given global 
standards of care, it is expected that the prophylactic regimen will be initiated prior to or 
immediately following a third epi[INVESTIGATOR_71245]  [Berntorp 1995; Manco-Johnson 2007; 
MASAC 2007] . The date of transition from epi[INVESTIGATOR_71246] a prophylaxis regimen must be 
captured on the eCRF.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
50 [IP_ADDRESS]. Prophylaxis Treatment 
It is anticipated that subjects will begin a prophylaxis regimen after confirmation of eligibility,  
prior to or immediately following the occurrence of a third hemarthrosis (joint bleed). The 
recommended initial prophyla ctic regimen is 50 IU/kg weekly. Adjustments to the dose and 
dosing interval can be made based upon available incremental recovery data, subsequent FIX 
activity levels, level of physical activity , and bleeding pattern, in accordance with local standards 
of care for a prophylactic regimen.   
Subjects and parents/caregivers  will be instructed to administer rF IXFc at home or to have it 
administered by a qualified professional under the direction of the Investigator or given at the 
clinic. Treatment will continue until the subject has reached at least 50 EDs to rFIXFc  study drug 
or the end of study is declared, see Section  7.5).  
10.2.3. Treatment of Bleeding Epi[INVESTIGATOR_1841]  
[IP_ADDRESS]. Definitions of Bleeding Epi[INVESTIGATOR_71256], a bleeding epi[INVESTIGATOR_71257]: A bleeding epi[INVESTIGATOR_71258] a bleed, and ends no more than [ADDRESS_77510] reports a bleeding epi[INVESTIGATOR_71259], and is treated with study 
drug, it will be classified as 1 of 2 types: spontaneous or traumatic. The subject‚Äôs EPD will serve as the primary source document for bleeding epi[INVESTIGATOR_71260]. 
Spontaneous bleeding epi[INVESTIGATOR_1841]: Bleeding epi[INVESTIGATOR_71261] a parent/caregiver/subject  records a bleeding event when there is no  known contributing factor 
such as a definite trauma or antecedent ‚Äústrenuous‚Äù activity.  The determination of ‚Äústrenuous‚Äù is 
at the discretion of the Investigator and the parent/caregiver/subject  needs to be instructed by [CONTACT_3786]. 
Traumatic bleeding epi[INVESTIGATOR_1841]:  Bleeding epi[INVESTIGATOR_71262]/caregiver/subject  records a bleeding epi[INVESTIGATOR_71263] a known or believed 
reason for the bleed.  For example, if a subject were to exercise strenuously and then h ave a 
bleeding epi[INVESTIGATOR_71264], the bleeding epi[INVESTIGATOR_71265].  Target joint bleeding epi[INVESTIGATOR_71266] a known action led to 
bleeding into the joint. The Investigator should consider whether events resulting in a traumatic 
bleeding epi[INVESTIGATOR_71267]. 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
51 [IP_ADDRESS]. Information to be Recorded  for Bleeding Epi[INVESTIGATOR_71268]/caregiver must be issued with an EPD once eligibility has been 
confirmed and they have been enrolled ; from that point forward, all data regarding bleeding 
epi[INVESTIGATOR_71269] a bleeding epi[INVESTIGATOR_71270]‚Äôs home or at locations other than the study site mu st be entered into the EPD . The 
incidence of bleeding in this study will be obtained from EPDs , eCRFs, and medical records . If a 
subject has enrolled in the study, information from medical records on dosing and bleeding 
epi[INVESTIGATOR_71271] , according to the eCRF Completion Guidelines.  
It is recommended that subjects or parents/caregivers enter bleeding epi[INVESTIGATOR_71272].   
The Investigators and Clinical Monitors will ensure that there is consistency in bleeding epi[INVESTIGATOR_71273]‚Äôs medical record, IXRS, source documents, EPD, and eCRFs. During 
the clinic visits and monthly telephone calls with the subject‚Äôs parents/caregivers, the 
subject/parent/caregiver will be reminded about timely EPD completion and the Investigator will 
verify whether or not a bleeding epi[INVESTIGATOR_71274], and was ‚Äú spontaneous‚Äù or ‚Äútraumatic‚Äù 
(Section [IP_ADDRESS]).  
If, following this discussion, the Investigator judges that the classification by [CONTACT_423]‚Äôs parents/caregivers  was incorrect, the Investigator will document it in the subject‚Äôs medical 
records with the rationale for the new classification, and the eCRF, documenting the new 
classification of the bleeding epi[INVESTIGATOR_71275]‚Äôs parents/caregivers  agreed with this new classification.  With regard to dose changes, the 
Investigator‚Äôs classification of spontaneous or traumatic will be used (if different from the 
classification recorded in the EPD by [CONTACT_7071]/ caregiver). Both spontaneous and traumatic 
bleeding epi[INVESTIGATOR_71276]. 
Information collected in the EPD will include, but not be limited to, the following: 
‚Ä¢ the type of bleeding epi[INVESTIGATOR_1865] (e.g., spontaneous, traumatic) and if related to sports 
activity or physical activity  
‚Ä¢ the date the bleeding event occurred  
‚Ä¢ the dose administered to treat the bleeding epi[INVESTIGATOR_71277]  
‚Ä¢ the location of the bleed 
‚Ä¢ the reason for administering the dose (medical or nonmedical reasons [e.g., training for administration of study treatment])  
‚Ä¢ the caregiver's rating of treatment response  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
52 [IP_ADDRESS]. Determination of the rFIXFc Dose to Treat a Bleeding Epi[INVESTIGATOR_71278]‚Äôs clinical condition, 
known PK inform ation (including  Table 1), type and severity of the bleeding event (see 
Appendix A  for guidance on dosing), and input from the Medical Monitor, if necessary. 
[IP_ADDRESS]. Procedure to Treat the Bleeding Epi[INVESTIGATOR_71279], all bleeding epi[INVESTIGATOR_71280] . 
Dosing calculations should be performed as described in the DHA an d summarized in 
Section 10.1.1 of this protocol. 
Subjects and their parents/caregivers  should be instructed to treat at the first sign of a bleeding 
epi[INVESTIGATOR_71281] a single dose of rFIXFc. Most bleeding epi[INVESTIGATOR_71282] a single 
dose of rFIXFc. See Section  [IP_ADDRESS] and  Appendix A  for rFIXFc dosing guidance. 
‚Ä¢ If the bleeding epi[INVESTIGATOR_71283] a single IV dose of rFIXFc, the subject will return to the schedule of dosing used prior to the bleeding epi[INVESTIGATOR_1865]. 
‚Ä¢ If the bleeding epi[INVESTIGATOR_71284] [ADDRESS_77511]‚Äôs parents/caregivers  should contact [CONTACT_71350]. 
Administration of a second dose of rFIXFc as follow- up treatment will be determined 
by [CONTACT_71351]‚Äôs clinical condition. Once the bleeding event 
resolves, the subject will return to the rFIXFc dosing schedule used prior to the 
bleeding epi[INVESTIGATOR_1865]. 
‚Ä¢ If the bleeding epi[INVESTIGATOR_71285] 2 doses (initial and follow -up 
treatments) of rFIXFc, the subject‚Äôs parents/caregivers  should contact [CONTACT_71352]. A third dose of rFIXFc will be administered within [ADDRESS_77512]‚Äôs clinical 
condition. Once the bleeding event resolves, the subject will return to the rFIXFc dosing schedule used prior to the bleeding epi[INVESTIGATOR_1865]. 
‚Ä¢ If the bleeding event has still not resolved with 3 dos es (initial and 2  follow-up 
treatments) of rFIXFc, the Investigator should consult with the Medical Monitor to 
determine if the subject should be withdrawn from the study. See Section  11. 
[IP_ADDRESS]. Dose and/or Interval Modification Following Bleeding Epi[INVESTIGATOR_71286]  [IP_ADDRESS] for guidance  on dose and/or interval modification. 
10.2.4. Inhibitor Testing  
Subjects will be tested for inhibitor and anti -rFIXFc antibody formation at each clinic visit.  
Samples for anti -rFIXFc antibody testing (see Section 10.2.5) will be collected at the same 
timepoint when any samples are collected for inhibitor testing, including confirmatory and 
Protocol 998HB303  Version [ADDRESS_77513] also be conducted at ED Milestone Visits, as described in 
Section [IP_ADDRESS]. If these do not align with a scheduled study visit, an additional visit must be 
scheduled to complete this testing.  Additional unscheduled testing for inhibitors may be 
performed if required by  [CONTACT_71353], and inhibitor test results  must be recorded on 
the eCRF . 
Testing for inhibitors must also be performed [ADDRESS_77514] Postoperative V isit (see Section  4.2.3). For minor 
surgeries, testing for inhibitors will only be performed if indic ated by [CONTACT_71354], according to local standard of care.  
A valid inhibitor test result is required from the ET/EOS Visit.  An unscheduled visit may be 
required to repeat inhibitor testing  under this protocol if the ET/EOS Visit inhibitor test is not 
evaluable, or to obtain samples to confirm a positive inhibitor test result.   
In addition, if inhibitor development is suspected at any time during the study ( e.g., the expected 
plasma FIX activity levels are not attained or if bleeding is not c ontrolled with an expected 
dose), the subject will be tested for inhibitors by [CONTACT_2237].   
A positive inhibitor test result is defined as an inhibitor test result of ‚â•0.60 BU/mL that is 
confirmed by a second test result of ‚â•0.60 BU/mL from a s eparate sample, drawn [ADDRESS_77515] with a result of ‚â•0.60 and <5.00 BU/mL.  A high titer inhibitor is defined as ‚â•5.00 BU/mL.  Subjects with discrepant 
inhibitor test results (initial low titer result followed by [CONTACT_71355]) should have repeat inhibitor te sting performed by [CONTACT_71356] a separate sample, drawn [ADDRESS_77516] results are <5.00  BU/mL, the inhibitor is considered low titer. If [ADDRESS_77517] results are 
‚â•5.00 BU/mL, the inhibitor is considered high titer.  
10.2.5. Anti-rFIXFc Antibody Testing 
At the same timepoints that samples are drawn for inhibitor testing  (see Section 10.2.4), blood 
samples will be collected for anti-rFIXFc antibody  testing, including 
back up and archiving samples.  Anti-rFIXFc antibody samples will be collected when in hibitor 
samples are collected for confirmatory and unscheduled inhibitor tests, tests for suspected 
inhibitor development, and as required before and after surgery. Samples  may also be collected 
and archived at the time of any clinical event deemed relevan t to inhibitor or anti- rFIXFc 
antibody testing.   
 

Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
54 10.2.6. Immune Tolerance I nduction 
[IP_ADDRESS]. Inhibitor Subgroup 
Subjects developi[INVESTIGATOR_71287]. Subjects with confirmed or suspected inhibitors may receive 
by[CONTACT_71357]. For more information on the use of by[CONTACT_71358] [IP_ADDRESS].  
[IP_ADDRESS]. Low Titer Inhibitors  
Subjects developi[INVESTIGATOR_71288]. These subjects will continue 
with the schedule of assessments in Section  [IP_ADDRESS] and Section  [IP_ADDRESS].  
If the Investigator determines that bleeding is no longer reliably controlled with rFIXFc in a 
subject with a positive low titer inhibitor, the subject will be eligible for ITI (see 
Section [IP_ADDRESS]).  If the subject declines to undergo or continue ITI, they will be withdrawn from 
the study. Subjects undergoing an ITI regimen will follow the schedule of assessments in 
Section 4.2.4, in addition to any other ITI regimen- specific assessments required.   
[IP_ADDRESS]. High Titer Inhibitors  
Subjects developi[INVESTIGATOR_71289] (see Section [IP_ADDRESS]).  If 
the subject declines to undergo or continue ITI, they will be withdrawn from the study. Subjects undergoing an ITI regimen will follow the schedule of assessments in Section 4.2.4, in addition 
to any other ITI regimen -specific assessments required . 
[IP_ADDRESS]. Use of By[CONTACT_71359] (aPCC [FEIBA] or rFVIIa [NovoSeven]) at the discretion of the Investigator and within labeled dosing 
recommendations for the specific by[CONTACT_71360]. The Investigator may prescribe by[CONTACT_71361] a high clinical suspi[INVESTIGATOR_71290]. When possible, bleeding should be confirmed via physical examination and/or imaging 
prior to administration of a by[CONTACT_71360]; Confirmation of bleeding should not cause any 
unnecessary delay in the start of treatment, as judged by [CONTACT_737]. In the event of an emergency, prior consultation with the Investigator is not required before administration of a 
by[CONTACT_71360]; however, the Investigator must be notified of such use.  
In subjects with low- titer inhibitors, bleeding ev ents may be controlled with increased doses of 
replacement FIX to overwhelm the inhibitor by [CONTACT_71362]. In subjects with high- titer 
inhibitors, bleeding may be treated with by[CONTACT_71363], which can by[CONTACT_71364]. 
During the study, the Inves tigator will determine if increased doses of replacement FIX or use of 
by[CONTACT_71365].  
During ITI treatment, subjects may also receive by[CONTACT_71366] a high clinical suspi[INVESTIGATOR_71290]. The use of by[CONTACT_71367] 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
55 agents in the setting of ITI requires awareness of FIX activity levels and close monitoring for 
cessation of bleeding events.  
It is recommended that Investigators discontinue the use of by[CONTACT_71368] <0.6 BU/mL (negative titer, or values considered negative per local laboratory reference) or once rFIXFc provides sufficient hemostatic control, as judged by [CONTACT_737].  
The prophylactic use of by[CONTACT_71369]. 
All use of by[CONTACT_71370]. 
[IP_ADDRESS]. Immune Tolerance Induction Therapy  
Subjects who develop a positive low titer inhibitor that cannot be adequately managed with 
rFIXFc or who develop a positive high titer inhibitor (‚â•5.00 BU/mL)  will be eligible to undergo 
ITI with rFIXFc.  The Medical Monitor will work with the Investigator to a scertain an established 
ITI regimen of the Investigator‚Äôs choice, using rFIXFc.  The ITI regimen plan must be approved 
for each subject by [CONTACT_71371] ‚Äôs Study Medical Director.  The ITI regimen can be modified 
during this study, but requires re -approval by [CONTACT_71372]‚Äôs Study Medical Director.   
In order to use rFIXFc in an ITI regimen plan, t he subject  or their parents/legal guardian s must 
sign a separate consent and the subject must provide assent, as applicable, at or prior to the Pre -
ITI Assessment Visit (ITI Week 0).  
rFIXFc will be provided for a period of up to 24 months under an ITI protocol. The 24-month duration is based on data from the North American Immune Tolerance Registry, which demonstrated a median time to completion of therapy of 11.6 months [Dimichele 2009] .  
‚Ä¢ The ITI regimen must provide adequate oversight to detect and manage potential 
complications associated with ITI in FIX -deficient subjects, including nephrotic 
syndrome and severe allergic reactions.  Please see the Schedule of Events for the ITI 
Visits (Section 4.2.4) for procedures to be performed during the ITI treatment period.  
 
 
 
 
 
  
 
 
 

Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
56  
 
IR c
alculations will be performed on results obtained from the predose and postdose FIX activity 
samples collected under the following conditions for both the initial and the confirmatory IR 
assessment : 
‚Ä¢ The subject must be in a non- bleeding state , after at least a 72 -hour washout .  
‚Ä¢ At the clinic, a predose FIX activity sample will be collected within 30 minutes prior to 
the start of injection . 
‚Ä¢ An rFIXFc dose of 50 IU/kg will be given . The actual potency shown on the vial must be 
used to calculate the units of rFIXFc and the volume to inject , as described in 
Section 10.1.1.  
‚Ä¢ A postdose FIX ac tivity sample will be collected 10  (¬±5) minutes after the end of the 
rFIXFc injection.  
The reference IR value (expected recovery), which is the basis for the second criteria for 
complete ITI success, is defined below:  
   
  
 
 
 
  
 
  
 
  
If the criteria for success have not been met, the subject may remain on ITI at the discretion of 
the Investigator, up to a total duration of ITI of [ADDRESS_77518] will be 
required to perform the assessments of the ET/EOS Visit for ITI (see Section  4.2.4).  
Subjects who choose to discontinue ITI prior to meeting the criteria for successful immune tolerance will perform the assessments of the ET/EOS Visit for ITI (see Section  4.2.4) and then 
be withdrawn from the study. 

Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
57 [IP_ADDRESS]. Treatment of Bleeding Epi[INVESTIGATOR_71291]‚Äôs discretion, activated prothrombin complex concentrates, recombinant 
activated coagulation factor VII, and rFIXFc can be used to treat active bleeding or to provide 
surgical hemostasis during ITI.  
Use of immunomodulatory agents during ITI is allowed  at the Investigator‚Äôs discretion.   
10.2.7. Surgery 
Minor surgery is allowed at any time during the study.  Major surgery will only be allowed in the 
study after the subject has had at least [ADDRESS_77519] will be withdrawn 
from the study.  
In addition, subjects who require major surgery may receive rFIXFc if: 
1. The surgery occurs within the contracted Institution for the study and/or a separate 
agreement has been executed, permitting the use of study drug and Bioverativ ‚Äôs rights to 
data generated in the study at an alternative Institution deemed appropriate by [CONTACT_1268] [INVESTIGATOR_1461].  
2. The Investigator and/or appropriate qualified/licensed delegate is available to: 
a. Administer all rFIXFc doses required during surgery and during postoperative 
rehabilitation (if applicable).   
b. Provide medical oversight and guidance throughout the duration of the preoperative and the intraoperative periods. 
Surgeries, elective or emergent, will be classified as major and minor as follows:  
‚Ä¢ Major surgery is defined as any surgical procedure in which a major body cavity is 
penetrated and exposed or for which a substantial impairment of ph ysical or 
physiological function is produced (e.g., laparotomy, thoracotomy, craniotomy, joint 
replacement, or limb amputation).   
‚Ä¢ Minor surgery is defined as any surgical procedure that does not qualify as major 
(e.g., minor dental extractions, port placement or removal, incision and drainage of 
abscess, or simple excisions).   
All major surgeries will be reported as SAEs, even if the surgery does not otherwise meet the definition of an SAE.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
58 Samples for determination of predose FIX activity levels and inhibitor formation will be 
collected prior to the dose of rFIXFc given for the surgery, and FIX recovery levels will be 
sampled 10 (¬± 5) minutes after the end of the rFIXFc injection.  
For major surgeries, a repeat blood draw for FIX activity should be taken approximately [ADDRESS_77520]/ 
parent/caregiver should not enter these doses in the EPD. 
Bleeding caused directly by [CONTACT_71373], although undesired or unexpected 
bleeding during or after surgery should be recorded on the eCRF.  
[IP_ADDRESS]. Surgical Period  
For all elective surgeries, subjects will begin the surgical period with their first dose of rFIX Fc 
given for the surgery (i.e., the pre-surgery dose). This is the preoperative period of the surgery. 
The intraoperative period is defined as the time from when the surgery begins to the time when 
the surgery is completed. The postoperative period is defi ned as the time period following the 
end of surgery throu gh the time when the  subject can return to their regular pre -surgery regimen , 
as judged by [CONTACT_737]/Surgeon.  
See Section  4.2.[ADDRESS_77521]/subject‚Äôs caregiver after 
the day of surgery to determine when the subject returns to their regular pre -surgery regimen.  For 
minor surgeries, pre-surgery assessments of FIX activity, inhibi tor, and anti-rFIXFc antibody, 
and hematology and blood chemistry on the day of surgery are only to be performed if indicated 
by [CONTACT_71374], according to local standard of care. The Investigator or Surgeon‚Äôs 
assessment of response is conducted on the day of surgery for minor surgeries; for major surgeries, the assessment occurs 24  hours after surgery and at the Postoperative Visit (1 to 
2 weeks after surgery).   
[IP_ADDRESS]. Dosing During Surgery  
For subjects who require emergent or elective surgery during the study period, the target FIX levels for the proposed procedure will be those deemed appropriate by [CONTACT_71375]. Recommendations for the appropriate dosing regimen of 
rFIXFc during the surgery may be discussed  between the Investigator and Medical Monitor 
taking factors such as standard doses of FIX for the type of surgery, the clinical status of the 
subject, and incremental recovery data for the subject into consideration.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
59 [IP_ADDRESS]. Rehabilitation Period  
If surgery -related dosing is to be continued during postoperative rehabilitation, the dose of 
rFIXFc will be adjusted to achieve a trough at a sufficient level to maintain hemostasis, including 
during physical therapy.  
Subjects will return to their pre -surgery regimen o nce all dosing for the postoperative period has 
been completed.  
10.3. Treatment Precautions  
Epi[INVESTIGATOR_41217], ant ihistamine  for IV injection, and any other 
medications and resuscitation equipment for the emergency management of anaphylactic 
reactions must be available in the room where the subject‚Äôs first injection of rFIXFc 
(commercially available rFIXFc and/or study drug) is being performed.  The subject‚Äôs first 
injection of rFIXFc study drug after the confirmation of eligibility  must be pe rformed by [CONTACT_71376]. In addition, the 
subjects or parents/caregiver s (as appropriate) will be provided with specific instructions by [CONTACT_71377], including how to seek 
emergency medical treatment.   
10.4. Modification of Dose and/or Treatment Schedule  
Information on modifications to the dose and treatment schedule can be found in Section  7.3.2.  
10.5. Non-Medical Treatment With rFIXFc  
During the study, subjects‚Äô parents/caregivers or subjects may attend training sessions on administration of rFIXFc.  Administration of rFIXFc for tra ining purposes will be considered 
nonmedical treatment.  Such training is permitted and must be recorded in the EPD . However, 
subject/parent/caregiver  administration  with the first dose of rFIXFc must be performed under 
supervision in the clinic . Data from this time period will be excluded from the analysis of 
consumption.  
10.6. End of Treatment  
Any subject who reaches at least [ADDRESS_77522] completed treatment.   
For subjects undergoing ITI with rFIXFc, the end of treatment  occurs when : 
1. The subject has achieved successful immune tolerance as defined in Section  10.2.[ADDRESS_77523] to end treatment because 1 of the following has occurred: 
1. The subject has met criteria for early withdrawal ( Section 11).  
2. Study stoppi[INVESTIGATOR_4989] ( Section 7.4). 
3. EOS has been reached (Section  7.5).  
Upon ending treatment for any of the reasons described above, the subject will return to the site 
for the ET/EOS visit. 
The Final Safety Follow -up Visit (by [CONTACT_52062]) will be conducted within 14 (+7) 
days after the last dose of rF IXFc to assess the subject‚Äôs status, collect AEs and/or SAEs, collect 
concomitant medications and procedures, and follow up on open AEs and SAEs 
(Section [IP_ADDRESS]). 
10.7. Treatment Compliance  
Compliance with treatment dosing is to be monitored and recorded by [CONTACT_6624].  The instructions 
provided in the DHA must be followed, as summarized in Section  10.1.1 of this protocol.  
For the doses that will be administered at the study site, the study treatment will be administered under controlled conditions by [CONTACT_71378]; therefore, full compliance with study 
treatment is anticipated.   
For between visit administration, subjects‚Äô parents or caregivers will administer (or older 
children will self -administer) rFIXFc and will record treatment in the EPD. The EPD will be 
reviewed during periodic calls to the subject‚Äôs parents/caregiver and at each clinic visit.   
10.8. Concomitant Therapy and Procedures  
The use of concomitant therapi[INVESTIGATOR_71292]‚Äôs 
eCRF according to instructions for eCRF completion. AEs related to administration of these therapi[INVESTIGATOR_71293].  
10.8.1. Concomitant Therapy  
A concomitant therapy is any drug or substance administered from 30 days prior to the Screening Visit through the Final Safety Follow -up Visit/Telephone Call.  For subjects who are receiving 
breast milk , the mother will provide consent to collect the concomitant medication s that she is 
taking (as part of the main parental consent) . The mother‚Äôs concomitant medications will not be 
collected if the breast milk is derived from a source other than the mother, if the mother will not 
consent, or if the mother is no longer breastfeeding. Refusal of the mother to provide consent for 
collection of her concomitant medication  data will not affect the eligibility of the subject to 
participate  in the study. The list of disallowed concomitant medications below does not apply to 
the mother‚Äôs medications .  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
61 Subjects (and their parents/caregivers)  should be instructed that the subject not start taking any 
new medications, including nonprescription drugs and herbal preparations, unless they have 
received permission from the Investigator.  
Allowed Concomitant Therapy 
Therapy considered necessary for the subject‚Äôs welfare, including routine immunizations, may be 
given at the discretion of the Investigator. Immunomodulatory therapi[INVESTIGATOR_71294]‚Äôs discretion if administered as part of an approved ITI regimen. By[CONTACT_71363] (e.g., aPCC [FEIBA], rFVIIa [NovoSeven]) are allowed in subjects with confirmed or suspected 
inhibitors as outlined in Section [IP_ADDRESS]. All such therapy must be recorded in the eCRF. The 
prophylactic use of by[CONTACT_71379].  
Disallowed Concomitant Therapy 
No other drug under investigation may be used concomitantly with the study treatment. Subjects 
are not allowed to participate concurrently in another clinical study.   
The following concomitant medications are not permitted during the study: 
‚Ä¢ acetylsalicylic acid  
‚Ä¢ current systemic treatment with chemotherapy and/or other immunosuppressant 
drugs. Use of steroids for treatment of asthma or management of acute allergic 
epi[INVESTIGATOR_71295] -threatening epi[INVESTIGATOR_71249] . Treatment in these 
circumstances should not exceed a 14 -day duration.  
‚Ä¢ any other FIX product (exception allowed for 1 emergency or accidental use)   
10.8.2. Concomitant Procedures  
A concomitant procedure is any therapeutic intervention (e.g., surgery/biopsy, physical therapy) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed from 30 days prior to Screening Visit until the Fin al Safety Follow -up Visit/Telephone Call.  The 
reason for all concomitant procedures performed during the study will be documented in the medical records and recorded in the eCRF.   
10.9. Continuation of Treatment   
No further provisions are made for access to the study treatment.  If rFIXFc is proven to be 
beneficial, all regulatory requirements regarding poststudy access will be met.   
Protocol 998HB303  Version [ADDRESS_77524] permanently discontinue study treatment and be withdrawn from the study if any 
of the following occur: 
‚Ä¢ The subject is found to have FIX  activity >2% or a positive inhibitor based on central 
laboratory results from samples collected during the screening period  
‚Ä¢ Development of a Grade 2 or greater allergic drug reaction in association with the 
administration of rFIXFc, as defined below by [CONTACT_71380] ( WHO) scale 
[WHO Handbook 1979] : 
‚àí Grade 2: bronchospasm; no parenteral therapy needed 
‚àí Grade 3: bronchospasm; parenteral therapy required 
‚àí Grade 4: anaphylaxis  
‚Ä¢ Development of a positive inhibitor as defined in Section 10.2.4, either a low titer 
inhibitor with bleeding that is no longer reliably controlled with rFIXFc or a high titer 
inhibitor, and opting not to undergo or continue ITI 
‚Ä¢ Use of FIX products other than rFIXFc (exception allowed for 1 emergency or accidental use) ; a further exception is the use of activated prothrombin complex 
concentrate for subject s developi[INVESTIGATOR_71296] (see Section  [IP_ADDRESS]) 
‚Ä¢ Development  of any condition that precludes subjects  from complying with the study 
procedures 
‚Ä¢ A medical emergency that necessitates discontinuation of treatment  
‚Ä¢ Judgment of the Investigator: a subject may have treatment permanently discontinued 
if, in the opi[INVESTIGATOR_689], it is not in the subject‚Äôs best interest to continue 
with the study treatment 
‚Ä¢ The parent/legal guardian can withdraw the subject from the study, or the subject can 
withdraw from the study, at will at any time  
‚Ä¢ At the discretion of the Investigator or Sponsor for noncompliance 
The reason for the subject‚Äôs withdrawal from the study must be recorded in the subject‚Äôs eCRF.  
For any subject who is not responding to treatment with rFIXFc, as determined by [CONTACT_3786], a decision will be made with the Sponsor whether to continue the subject in the study.  
Protocol 998HB303  Version [ADDRESS_77525] from the study, the E T/EOS Visit assessments 
will be performed as described in Section 4.2.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
64 12. STUDY TREATMENT  MANAGEMENT  
Refer to the Study Reference Manual for full details regarding rFIXFc.  Study site staff should 
refer to the DHA located in the Study Reference Manual for specific instructions on the 
handling, preparation, administration, and disposal of rFIXFc. The DHA su persedes all other 
references (e.g., Investigator‚Äôs Brochure and protocol).   
The study treatment, rFIXFc, must be stored in a secure location.  Accountability for study 
treatment is the responsibility of the Investigator.  More details concerning this responsibility are 
included in Section 12.1.4.  
Study treatme nt must be dispensed only by a P harmacist or medically qualified staff. Study 
treatment is to be dispensed only to parent s/legal guardians of subjects enrolled in this study or 
Sponsor-approved designees.  Once study treatment is prepared for a subject, it can only be 
administered to that subject.  Study treatment vials are for 1 -time use only; any study treatment 
remaining in the vial after preparation of a dose should not be used for another subject.  
12.1. rFIXFc (BIIB029)  
rFIXFc is supplied in a kit that contains several components: a vial of lyophilized drug, a 
prefilled diluent syringe, a vial a dapter, and a winged infusion set (see DHA for further details). 
The lyophilized powder is in a clear glass vial containing 250, 500, 1000, or 2000 IU of rFIXFc 
(nominal strengths). The drug product is reconstituted with a prefilled diluent syringe containing 
 sodium chloride. After reconstitution of the lyophilized drug product, the 
concentrations of excipi[INVESTIGATOR_71297] 250, 500, 1000, and 2000 IU/vial strengths are  
L-histidine,  sucrose,  mannitol,  polysorbate 20, and  sodium chloride.  
The label will comply with local labeling requirements.   
12.1.1. rFIXFc Preparation  
At the first visit when study drug is given , the individual preparing the study treatment should 
first carefully review the instructions provided in the DHA be fore preparing the dose assigned 
for the subject.  The Pharmacist or medically qualified  staff member will provide the Investigator or clinical staff 
with enough rFIXFc kits for treatment until the subject‚Äôs next clinic visit. This will be 
documented accor ding to Section 12.1.4.  
If the packaging is damaged  or if there is anything unusual about the appearance or attributes of 
the vials of rFIXFc or syringes containing the diluent, it should not be used. The vial or syringe in question should be saved at the study site and the problem immediately reported to the Clinical Monitor.  

Protocol 998HB303  Version [ADDRESS_77526] be stored in a secure location.  The rFIXFc kit should be 
stored on site at 2¬∞C to 8¬∞C in a monitored and  locked refrigerator with limited access . If the 
refrigerator does not have a lock, the refrigerator must be located in a locked room. For the most 
up-to-date storage requirements, follow the instructions provided in the DHA.  
12.1.3. rFIXFc Handling and Disposal  
The Investigator must return all used and unused kits of rFIXFc as instructed by [CONTACT_71381]. The instructions for returning the kits  will be provided at 
the time the request is made by  [CONTACT_71371] .  
If any Bioverativ  supplies are to be destroyed at the study site, the Institution or appropriate site 
personnel must obtain prior approval from Bioverativ  or designee, by [CONTACT_1541], in writing, the 
destruction policy or details of the method of destruction. After such destruction, Bioverativ  or 
designee must be notified, in writing, of the details of the study treatment destroyed (e.g., lot or 
kit numbers, quantities), the date of destruction, and proof of destruction.  
12.1.4. rFIXFc Accountability  
Accountability for study treatment is the responsibility of the Investigator.  The study site must 
maintain accurate records demonstrating dates and amount of study treatment received, to whom 
dispensed (subject- by-subject accounting), amount returned by [CONTACT_423], and accounts of any 
study treatment accidentally or deliberately destroyed  or lost. These records  will be routinely 
reviewed by [CONTACT_71382].  
Unless otherwise notified, t he subject‚Äôs parents/legal guardians  should return all vials (used and 
unused) at each clinic visit for full medication exchange and accountability. At the end of the 
study, reconciliation must be made between the amount of drug product supplied, dispensed, and 
subsequently destroyed, lost, or re turned to Bioverativ . A written explanation must be provided 
to Bioverativ  for any discrepancies.   
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
66 13. EFFICACY AND ACTIVITY ASSESSMENTS  
See Section 4.2 for the timing of assessments.   
13.1. Clinical Efficacy Assessments  
The following clinical tests/assessments will be performed to assess the efficacy of  rFIXFc: 
‚Ä¢ Recording of bleeding epi[INVESTIGATOR_71298]/Investigator; recording of bleeding epi[INVESTIGATOR_71299]/legal guardian s/subjects or at locations other 
than the study site .  
‚Ä¢ Assessment of response  to bleeding epi[INVESTIGATOR_71300] 4- point scale by [CONTACT_71383][INVESTIGATOR_71301] ; assessment  of 
all other bleeding epi[INVESTIGATOR_71302]/legal guardian s/subjects. See 
Appendix B .  
‚Ä¢ Physician‚Äôs global assessment of the subject‚Äôs response to their  treatment regimen 
using the 4- point scale.  See Appendix C .  
13.2. Laboratory Efficacy Assessments  
Not applicable.   
13.3. Pharmaco kinetic Assessments 
Pre- and postdose s amples are to be collected at the Baseline IR Visit for the calculation of 
incremental recovery  (the Screening sample may replace the predose Baseline IR sample if the 
subject has not received any dose of any FIX -containing product prior to the dose for the 
baseline IR assessment, see Section  9.1.4). In addition, s amples for measurement of FIX activity 
levels are to be collected at  all Interim Visits during the prophylaxis regimen when rFIXFc is 
administered in the clinic  (see Section  7.3.2). For subjects undergoing ITI who have a confirmed 
negative inhibitor, samples are to be collected for the calculation of IR (see Section  4.2.4 and 
Section [IP_ADDRESS] for details ). Sample collection for FIX activity assessments at other timepoints 
during ITI treatment is at the discretion of the Investigator.  Samples collected at the Baseline IR, 
interim visits, and if applicable during ITI treatment will be analyzed for FIX activity at a central 
laboratory. Procedures for collecting, processing, storing, and transporting to the central 
laboratory are fully described in the Study Laboratory Manual.  
For subjects undergoing surgery, samples are to be collected according to the schedule in 
Section 4.2.3. While hospi[INVESTIGATOR_057], blood will be drawn daily to be tested at the local laboratory 
for FIX activity so that monitoring of the subject can occur in real time.   
See Section  4.2 for the timing of assessments.   
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
67 13.4. Pharmacodynamic Assessments  
Not applicable.   
13.5. Additional Assessments  
13.5.1. Factor 9 Genotypi[INVESTIGATOR_007] (Optional)  
For subjects whose genotype  is not known, with consent from the subject‚Äôs parents /legal 
guardians , a sample will be drawn for analysis  at the predose Baseline IR Visit (or at a 
subsequent visit if blood volume is limiting at that visit, see Section  4.2.1, Section  [IP_ADDRESS], and 
Section [IP_ADDRESS]). The subject‚Äôs parent/legal guardian may provide consent in order to receive this 
testing at any time during the Treatment Period.  This is not an inclusion or exclusion criterion; 
refusal of  the subject‚Äôs parent s/legal guardian s, or local laws precluding this test, would not 
exclude the subject from the study.  
Genotypi[INVESTIGATOR_71303].  Genotypi[INVESTIGATOR_71304].  The development of an inhibitor to treatment with 
factor concentrates is the single most serious complication of factor replacement.  One of the 
decisive risk factors for the development of inhibitors is the type of mutation (e.g., full or missense) that codes for a protein that may be absent, truncated, or present but not functional. 
There is a correlation between the resultant pro tein and the likelihood of developi[INVESTIGATOR_71305] [Oldenburg and Pavlova 2006] .  
There is [ADDRESS_77527] the genotypi[INVESTIGATOR_71306]. Analysis will take approximately 1  month, and the Investigator at the site will be 
informed of the result.  
 
 
 
Genotypi[INVESTIGATOR_71307] s will be retained indefinitely (unless prohibited by [CONTACT_1769]).   
13.5.2. Health Outcomes Related to Hemophilia  
Assessments of h ealth outcomes related to hemophilia will include: 
‚Ä¢ number of hemophilia-related hospi[INVESTIGATOR_602], excluding planned hospi[INVESTIGATOR_71308] 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
68 ‚Ä¢ number of hemophilia- related hospi[INVESTIGATOR_30874]  
‚Ä¢ number of hemophilia-related emergency room visits 
‚Ä¢ number of hemophilia- related physician visits excluding study visits  
‚Ä¢ number of days off school or day care (kindergarten) 
‚Ä¢ number of days off work for parent/guardian or caregiver (demographic data for 
caregivers may be collected at the Screening Visit)  
‚Ä¢ primary method of administering rFIXFc  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
69 14. SAFETY ASSESSMENTS 
See Section 4.2 for the timing of assessments.   
14.1. Clinical Safety Assessments  
The following clinical assessments will be performed to assess the safety profile of  rFIXFc: 
‚Ä¢ physical examination  
‚Ä¢ medical and surgi cal history  
‚Ä¢ height 
‚Ä¢ weight 
‚Ä¢ vital sign measurements  (blood pressure, pulse rate, respi[INVESTIGATOR_697], and temperature) 
‚Ä¢ concomitant therapy and procedure  recording , including concomitant medications 
taken by [CONTACT_71384], unless the breast 
milk is derived from a source other than the mother or the mother has not consented 
‚Ä¢ AE and SAE recording 
See Section 4.2 for the  timing of assessments.   
14.2. Laboratory Safety Assessments  
The following laboratory tests will be performed to assess the safety profile of rFIXFc. All 
samples will be analyzed at a central laboratory.  Procedures for collection, processing, storing, 
and transporting the samples  are fully described in the Study Laboratory Manual. Sample volume 
restrictions are described in Section  14.6.  
‚Ä¢ hematology: white blood cell count and differential, red blood cell, hemoglobin, 
hematocrit, and platelet count 
‚Ä¢ blood chemistry: sodium, potassium, chloride, total protein, total bilirubin, gamma 
glutamyl transferase,  aspartate aminotransferase, alanine aminotransferase, alkaline 
phosphatase, blood urea nitrogen, serum creatinine, and glucose 
‚Ä¢ urinalysis  
See Section 4.2 for the timing of assessments.   
14.3. rFIXFc-Specific Safety Assessments  
The following assessment will be performed to determine the safety of rFIXFc:  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
70 ‚Ä¢ neutralizing antibody development (inhibitor) measured by [CONTACT_71385] -modified 
Bethesda assay  
14.4. Additional Assessments  
The following exploratory assessment will be performed:  
‚Ä¢ anti-rFIXFc antibodies (detection, titer, and specificit y) 
14.5. Archive Samples  
14.5.1. Archive Plasma Samples  
Plasma samples from each subject obtained at each sampling timepoint for inhibitor and 
anti-rFIXFc antibody testing  will be aliquoted into 2 vials where possible. These 2  aliquots will 
be shipped to the central laboratory in separate shipments (the second aliquot being a back-up 
sample in case of damage or loss during shippi[INVESTIGATOR_007]).  
Where the backup sample is not used, it will be stored ( archived) and may be used, if clinically 
or scientifically indicated, for  the following : 
‚Ä¢ testing for coagulation parameters 
‚Ä¢ lupus anticoagulant  
‚Ä¢ additional testing  (including testing for anti-rFIXFc antibody) in the event that a 
subject develops an inhibitor, or is suspected of having developed an inhibitor, or has an anaphylactic reaction to the study treatment  
‚Ä¢ testing for immunology (including testing for anti -rFIXFc antibody) or further 
coagulation assays or for clarification of any clinical or laboratory AE  
In addition to this, a portion of the above samples will continue to be archived until after 
completion of review by [CONTACT_71386] [EMA (EMA/CHMP/BPWP/144533/2009) 2011] in the case of  a positive inhibitor or clinical suspi[INVESTIGATOR_71309].  
No samples will be used for genetic analyses except F9 genotype retesting, if required(see 
Section 13.5.1 for further details ). 
14.6. Sample Volumes  
Subjects weighing <6 kg may require screening blood draws over multiple days in order to 
comply with maximum allowable blood draw volumes [European Commission 2008] . Examples 
of recommended blood draw volume limits per the European Commission guidance are provided 
in Table 2. Alternatively, individual investigators may choose to collect all samples using a 
Protocol 998HB303  Version [ADDRESS_77528] document the rationale. 
Local and/or regional guidelines regarding blood draw volumes may also apply. 
Table 2: Examples of Recommended Blood Draw Volume Limits   
Subject Weight (kg)  Blood Draw Limitsa (mL) 
Single Occasionb 4 weeksb 
3.5  2.8 8.4 
4.0  3.2 9.6 
4.5  3.6 10.8 
5.0  4.0 12.0 
5.5  4.4 13.2 
6.0  4.8 14.4 
6.5  5.2 15.6 
7.0  5.6 16.8 
7.5  6.0 18.0 
8.0  6.4 19.2 
8.5  6.8 20.4 
9.0  7.2 21.6 
9.5  7.6 22.8 
10.0  8.0 24.0 
a Based on an estimated  blood volume of 80 mL/kg 
b Based on European Commission guidance [European Commission 2008]  recommending that blood draw volumes 
not exceed 1% of total blood volume on a single occasion or 3% over a 4- week period.  
Protocol 998HB303  Version [ADDRESS_77529]. If necessary, appropriate medical intervention 
should be provided.  
At the signing of the  informed consent form ( ICF), each subject‚Äôs parent s/legal guardians  must 
be given the names and telephone numbers of study site staff for reporting AEs and medical 
emergencies.   
15.1. Definitions 
15.1.1.  Adverse Event  
An AE is any untoward medical occurrence in a pati ent or clinical investigation subject 
administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.  
Determination of whether an abnormal laboratory value meets the definition of an AE will be 
made by [CONTACT_737].  Although abnormal laboratory values are typi[INVESTIGATOR_71310], 
the following considerations may result in an abnormal laboratory value being considered an AE:  
‚Ä¢ A laboratory test result that meets the criteria for an SAE   
‚Ä¢ A laboratory test result that requires the subject to receive specific corrective therapy  
‚Ä¢ A laboratory abnormality that the Investigator considers to be clinically significant 
Bleeding epi[INVESTIGATOR_71311] ; however, the 
concomitant events associated with a bleeding epi[INVESTIGATOR_71312] 
(e.g., a fracture in an elbow).  Bleeding epi[INVESTIGATOR_71313] a serious criterion (Section  15.1.2 ) 
should be reported as an SAE.  Bleeding epi[INVESTIGATOR_71314] [IP_ADDRESS] and Section  13.1.  
15.1.2. Serious Adverse Event  
An SAE is any untoward medical occurrence that at any dose:  
‚Ä¢ results in death  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
73 ‚Ä¢ in the view of the Investigator, places the subject at immediate risk of death (a 
life-threatening event); however, this does not include an event that, had it occurred 
in a more severe form, might have caused death  
‚Ä¢ requires inpatient hospi[INVESTIGATOR_1081]  
‚Ä¢ results in persistent or significant disability/incapacity, or  
‚Ä¢ results in a congenital anomaly/birth defect  
An SAE may also be any other medically important event that, in the opi[INVESTIGATOR_689], 
may jeopardize the subject or may require intervention to prevent one of the other outcomes 
listed in the definition above. (Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency r oom or convulsions occurring at home that do not 
require an inpatient hospi[INVESTIGATOR_059].)  
[IP_ADDRESS]. Serious Pretreatment Event  
A serious pretreatment event is any event that meets the criteria for SAE reporting (as defined in 
Section 15.1.2) and occurs after signing of  the ICF, but before administration of rFIXFc 
(commercially available rFIXFc or  study drug ). A serious pretreatme nt event is to be reported on 
the SAE Form and faxed to Quintiles Pharmacovigilance within 24 hours of the study site staff 
becoming aware of the event (see Section 15.3.3); such an event will be recorded in the eCRF.  
Any serious adverse event  that occurs after the first dose of commercial ly available rFIXFc but 
prior to signing of  the ICF should be reported as a post-marketing event; such  an event will not 
be considered a serious pretreatment event  and will not be recorded in the eCRF. 
15.2. Safety Classifications  
15.2.1. Investigator Assessment of Events 
All events must be assessed to determine the following:  
‚Ä¢ If the event meets the criteria for an SAE as define d in Section  15.1.2. 
‚Ä¢ The relationship of the event to study treatment as defined in Section  15.2.2. 
‚Ä¢ The severity of the event as defined in Section  15.2.3. 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
74 15.2.2. Relationship of Events to Study Treatment  
The following definitions should be considered when evaluating the relationship of AEs and 
SAEs to the study treatment: 
Relationship of Event to Study Treatment  
Not related  An adverse event will be considered ‚Äúnot related‚Äù to the use of the investigational drug 
if there is not a reasonable possibility  that the event has been caused by [CONTACT_71387]. Factors pointing toward this assessment include, but are not limited to: the lack of reasonable temporal relationship between administration of the drug and 
the event, the presence of a biologically implausible relationship between the product 
and the adverse event, or the presence of a more likely alternative exp lanation for the 
adverse event.  
Related An adverse event will be considered ‚Äúrelated‚Äù to the use of the investigational drug if there is a reasonable possibility  that the event may have been caused by [CONTACT_71387]. Factors that point to ward this assessment include, but are not 
limited to: a positive rechallenge, a reasonable temporal sequence between administration of the drug and the event, a known response pattern of the suspected 
drug, improvement following discontinuation or dose reduction, a biologically 
plausible relationship between the drug and the adverse event, or a lack of an 
alternative explanation for the adverse event.  
15.2.3. Severity of Events  
The following definitions should be considered when evaluating the severity of AEs and SAEs:  
Severity of Event  
Mild Symptom(s) barely noticeable to subject or does not make subject uncomfortable; does not influence performance or functioning; prescription drug not ordinarily needed for 
relief of symptom(s) but may be given because of person ality of subject.  
Moderate Symptom(s) of a sufficient severity to make subject uncomfortable; performance of daily activity is influenced; subject is able to continue in study; treatment for symptom(s) may be needed. 
Severe Symptom(s) cause severe discomfort; symptoms cause incapacitation or significant 
impact on subject‚Äôs daily life; severity may cause cessation of treatment with study 
treatment; treatment for symptom(s) may be given and/or subject hospi[INVESTIGATOR_057].  
15.2.4. Expectedness of Events  
Expectedness  of all AEs will be determined by [CONTACT_71388]‚Äôs 
Brochure for rFIXFc.  
Protocol 998HB303  Version [ADDRESS_77530]- marketing event; such an event will not be 
recorded in the eCRF.   
15.3.2. Serious Adverse Events  
Any SAE experienced by [CONTACT_71389] -of-study Safety 
Follow-up Visit is to be reported on an SAE Form and recorded in the eCRF, regardless of the 
severity of the event or its relationship to study treatment.  SAEs must b e reported to Quintiles 
Pharmacovigilance and the designated personnel within [ADDRESS_77531] be reported within 24 hours of the study site 
staff becoming aware of the SAE .  
Subjects will be followed for all SAEs until the Safety Follow -Up Visit, which will be 14 (+7) 
days after the last dose.  Thereafter, the event should be reported to Quintiles Pharmacovigilance 
only if the Investigator considers the SAE to be related to study treatment. 
Any SAE ongoing when the subject completes the study or discontinues from the study will be 
followed by [CONTACT_71390], stabilized, or returned to baseline status.  
In this study, the following events are considered medically important and must be reported as SAEs: 
‚Ä¢ a subject develops an inhibitor, as defined in Section  10.2.4.  
‚Ä¢ a subject develops a Grade 2 or greater allergic reaction in association with 
administration of rFIXFc defined as follows using the Recommendations for Grading 
of Acute and Subacute Toxic Effects on the WHO scale [WHO Handbook 1979] : 
‚àí Grade 2: bronchospasm; no parenteral therapy needed 
‚àí Grade 3: bronchospasm; parenteral therapy required 
‚àí Grade 4: anaphylaxis  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
76 ‚Ä¢ a subject develops a vascular thrombotic event in association with the administration 
of rFIXFc, with the exception of IV injection site thrombophlebitis 
‚Ä¢ a subject undergoes major surgery  
Allergic reactions, including anaphylaxis , have been reported with FIX products. 
Hypersensitivity reactions have been reported with rFIXFc. These events often occur in close 
temporal relation with the development of FIX inhibitors . Subjects (as appropriate) and 
parents/legal guardians of subjects should be informed of early symptoms and signs of 
hypersensitivity reactions, including difficulty breathing, chest tightness, swelling of the face, 
rash, or hives. If such an event occurs while the subject is at home, the parents/legal guardians 
should be instructed to seek immedia te medical care for the subject.  The presence of inhibitors 
has been associated with allergic reactions with FIX replacement therapi[INVESTIGATOR_014] , including with 
rFIXFc. Subjects experiencing allergic reactions should be evaluated for the presence of an 
inhibitor.  
Subjects (as appropriate) and parents/legal guardians  of subjects will be informed of the early 
symptoms and signs of thrombotic phenomena, including pain and/or tenderness along a vein, 
unexpected swelling of an arm or leg without pain or tenderness, redne ss along a vein, low fever 
without any known reason (such as a cold or flu), sudden shortness of breath or difficulty 
breathing, or coughing, sudden chest pain, sudden severe headache or changes in vision, and 
numbness or tingling in arms or legs. If such an event occurs while the subject is at home, the 
parents/legal guardians will be instructed to seek immediate medical care  for the subject.  
15.3.3. Immediate Reporting of Serious Adverse Events  
In order to adhere to all applicable laws and regulations for reporting an SAE, the study site must formally notify Quintiles Pharmacovigilance  within 24 hours of the study site staff becoming 
aware of the SAE.  It is the Investigator‚Äôs responsibility to ensure that the SAE reporting 
information and procedures are used and followed appropriately.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
77 Reporting Information for SAEs 
Any Serious Event that occurs between  the time that the parents/legal guardian s have signed 
the informed consent and 14 (+7) days after the last dose of rFIXFc (up to last study 
visit/telephone call) must be reported to Quintiles Pharmacovigilance  within [ADDRESS_77532] be submitted  to Quintiles Pharmacovigilance regardless  of the following: 
‚Ä¢ whether or not the subject has undergone study- related procedures  
‚Ä¢ whether or not subject has received study treatment  
‚Ä¢ the severity of the event  
‚Ä¢ the relationship of the event to study treatment 
To report initial or follow -up information on a Serious Event, fax a completed SAE Form to 
Quintiles Pharmacovigilance at the country -specific fax numbers  provided in the Study 
Reference Manual.   
Any SAE must also be entered in the eCRF in the same timeframe.   
[IP_ADDRESS]. Deaths 
Death is an outcome of an event. The event that resulted in death should be recorded on the 
appropriate e CRF. All causes of death must be re ported as SAEs  within 24 hours of the site 
becoming aware of the event . The Investigator should make every effort to obtain and send death 
certificates and autopsy reports to Qu intiles Pharmacov igilance. The term death should be 
reported as an SAE only if the cause of death is not known and cannot be determined.  
15.3.4. Suspected Unexpected Serious Adverse Reactions  
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are SAEs that are unexpected and 
judged by [CONTACT_71391].  
Bioverativ  (or designee) will report S[LOCATION_003]Rs to the appropriate regulatory authorities and 
Investigators as required, according to local law.   
15.4. Procedures for Handling Special Situations  
15.4.1. Pregnancy   
The population under study is male; therefore, pregnancies will not be tracked.   
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
78 Congenital abnormalities/birth defects in the offspring of male subjects should be reported as an 
SAE when study drug-exposed conception occurs. 
15.4.2. Overdose  
An overdose is any dose of study treatment administered to a subject or taken by a subject that 
exceeds the dose assigned to the subject according to the protocol. For the purposes of this study, 
any prophylactic dose greater than 150 IU/kg will be considered an overdose. Doses greater than 
150 IU/kg will not be considered overdoses if they are given as part of epi[INVESTIGATOR_71232], 
treatment of a bleeding epi[INVESTIGATOR_1865], surgical management, or during the ITI regimen. 
Overdoses are not considered AEs  and should not be recorded as AEs on the eCRF; however , all 
overdoses must be recorded on an Overdose Form and faxed to Quintiles Pharmacovigilance  
within [ADDRESS_77533] be recorded on the dosing e CRF. 
15.4.3. Medical Emergency  
In a medical emergency requiring immediate attention, study site staff will apply appropriate medical intervention, according to current standards of care. The Investigator (or designee) should contact [CONTACT_71392]‚Äôs Medical Director. Refer to the Study Reference Guide‚Äôs Official 
Study Contact [CONTACT_71393].   
15.4.4. Unblinding for Medical Emergencies  
Not applicable.   
15.5. Safety Responsibilities  
15.5.1. Investigator Responsibilities  
The Investigator‚Äôs responsibilities include the following: 
‚Ä¢ Monitor and record all AEs, including SAEs, regardless of the severity or relationship to study treatment.  
‚Ä¢ Determine the seriousness, relationship, and severity of each event. 
‚Ä¢ Determine the onset and resolution dates of each event. 
‚Ä¢ Complete an SAE F orm for each SAE and fax it to Quintiles Pharmacovigilance  
within 24 hours of the study site staff becoming aware of the event. 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
79 ‚Ä¢ Pursue SAE follow-up information actively and persistently. Follow-up information 
must be reported to Quintiles Pharmacovigilance within 24 hours of the study site 
staff becoming aware of new information. 
‚Ä¢ Ensure all AE and SAE reports are supported by [CONTACT_71394]‚Äô medical records.  
‚Ä¢ Pursue AE follow-up informatio n until the  event has resolved or become stable.  
‚Ä¢ Report SAEs to local ethics committees, as required by [CONTACT_1769].  
The Investigator may delegate responsibilities for study- related tasks where appropriate to 
individuals sufficiently qualified by [CONTACT_8640], training, a nd experience, in accordance with 
International Council for Harmonisation  (ICH) - Good Clinical Practice (G CP). The Investigator 
should maintain a list of the appropriately qualified persons to whom significant study- related 
duties have been delegated.   
15.5.2. Bioverativ Responsibilities  
Bioverativ‚Äôs responsibilities include the following: 
‚Ä¢ Before study site activation and subject enrollment, the Clinical M onitor or designee 
is responsible for reviewing with study site staff the definitions of AE and SAE, as well as the instructions for monitoring, recording, and reporting AEs and SAEs. 
‚Ä¢ Bioverativ  is to notify all appropriate regulatory authorities, central ethics 
committees, and Investigators of SAEs, as required by [CONTACT_1769], within required time 
frames. 
Protocol 998HB303  Version [ADDRESS_77534] deviation, minimum, and 
maximum.  Categorical variables will be summarized by [CONTACT_71395].  
The objectives of the study and the endpoints to be analyzed are listed in Section  6.  
16.1. Demography and Baseline Disease Characteristics  
The analysis of demography and baseline disease characteristics will be based on the Safety Analysis Set and Full Analysis Set  (FAS), as appropriate. A subset of analyses may be 
performed based on the Supporting Analysis Set. D escription s of the Safety Analysis Set and 
Supporting Analysis Set are provided in Section 16.5.1 and a description of the  FAS is provided 
in Section  16.2.1. De mographics and baseline disease characteristics will be summarized 
categorically and/or with descriptive statistics, as appropriate.   
Demographic data to be tabulated will include, but not be limited to, age, race, weight, and geographic location.  
Baseline disease characteristics, based on general medical and surgical, hemophilia, and bleeding 
histories, will be summarized as follows.  General medical and surgical history will be 
summarized by [CONTACT_71396] a medical history in each of the 
major body system classifications.  Hemophilia history data to be tabulated will include but not 
be limited to genotype, types of blood products previously used, and other disease- and 
treatment -specific measures.  Bleeding history will include a summary of the number and types of 
bleeding epi[INVESTIGATOR_71315] [ADDRESS_77535] after exposure to rFIXFc study drug (the 
Inhibitor Subgroup) will have their efficacy data included up to the time of the last negative  
inhibitor test; efficacy data collected after the time of the last negative  inhibitor test will be 
summarized separately.   
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
81 16.2.2. General Methods of Analysis 
All efficacy endpoints are secondary. No imputation will be applied to any missing efficacy data.   
The efficacy and surgical/rehabilitation periods will be defined in the statistical analysis plan 
(SAP) for the purpose of determining the study periods during which data will be used for select 
efficacy analyses.  Data on bleeding and rFIXFc consumption will be based on the efficacy 
period; surgical evaluations will be based on the surgical/rehabilitation period.   
Analysis of efficacy endpoints that are visit -based wil l include data from all study visits whether 
or not in the efficacy period, unless that visit is coincidental with a surgical/rehabilitation period 
for a major surgery, in which case it would be excluded.  
16.2.3. Analysis of Efficacy Endpoints  
Annualized Bleeding Epi[INVESTIGATOR_71316]:  
Bleeding epi[INVESTIGATOR_71317] a per- subject basis and 
summarized by [CONTACT_71397] ( epi[INVESTIGATOR_71318]) and overall. This ABR will 
be calculated as the total number of bleeding epi[INVESTIGATOR_71319] a subject divided by [CONTACT_71398], 
multiplied by 365.25. The per -subject ABR will also be summarized for type of bleed 
(spontaneous, traumatic), location of the bleed, and spontaneous joint bleeding epi[INVESTIGATOR_1841], and for 
other subgroups of interest. The consumption of rFIXFc will be annualized in a similar fashion and summarized overall as well as for subgroups of interest.  
Other Efficacy Endpoints:  
The number of injections and dose per injection required to resolve bleeding will be summarized 
on both a per-bleeding-epi[INVESTIGATOR_36192] a per- subject basis, where the per -subject basis will be 
determined as the average over  all bleeding epi[INVESTIGATOR_71320] a given subject.  
The response to treatment for bleeding will be summarized by [CONTACT_71399][INVESTIGATOR_71321] (excellent, good, moderate, or none).  
These data will be summarized overall and for subgroups of interest.   
Other Efficacy Assessments: 
The total dose administered to resolve a bleeding epi[INVESTIGATOR_71322], and in the same manner as, the specified endpoints of number of injections and dose 
per injection for resolution of bleeding.  
The Investigator‚Äôs assessment of the subject‚Äôs overall response to their  rFIXFc regimen will be 
summarized for each study visit and across all visits for the number and percentage of outcomes 
classified as excellent, effective, partially effective, and ineffective.  Summaries will be provided 
overall.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
82 Treatment with rFIXFc, bleeding epi[INVESTIGATOR_1841], blood loss, and transfusions administered for major 
and minor surgeries will be provided in data listings. These assessments will be made during the 
various components of the surgical/rehabilitation period as appropriate (surgery, postoperative 
care, and rehabilitation).   
16.2.4. Additional/Exploratory Analysis of Efficacy Endpoints  
Other efficacy analyses may be conducted for exploratory purposes, including exploratory 
endpoints (health outcomes).  
16.3. Pharmacokinetics  
Incremental recovery data will be listed and summarized by [CONTACT_765].  For each subject, the observed 
incremental recovery estimated at each applicable visit will be averaged and summarized.  
PK paramete rs, such as IR, derived from assessments during ITI will be listed for each 
applicable subject.  PK parameters (IR) for subjects undergoing ITI will be determined by 
[CONTACT_71400]- stage clotting assay to facilitate 
assessment of ITI outcome.   
16.4. Pharmacodynamics  
Not applicable.   
16.5. Safety 
Unless specified otherwise in the SAP , safety data will be summarized overall. Subjects 
developi[INVESTIGATOR_007] a confirmed positive inhibitor test after exposure to rFIXFc study drug (the Inhibitor 
Subgroup) will have their safety data included up to the time of the last negative inhibitor test; 
safety data collected after the time of the last negative inhibitor test will be summarized separately.   
16.5.1. Analysis Population 
The Safety Analysis Set is defined as all subjects who receive at least 1  dose of rFIXFc, 
including study drug and/or commercially available rFIXFc . The primary safety analyses will be 
based on the Safety Analysis Set including the data collected on or after the time of the first 
injection of rFIXFc (study drug and/or commercially available  rFIXFc).  
The Supporting Analysis Set is defined as all subjects who receive at least 1  dose of rFIXFc 
study drug and meet the eligibility criteria (with screening FIX activity and inhibitor test results 
confirmed by [CONTACT_2237]).  Selected safety analyses may be based on the Supporting 
Analysis Set including the data collected on or after the time of the first injection of rFIXFc 
study drug.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
83 16.5.2. Methods of Analysis 
[IP_ADDRESS]. Occurrence of Inhibitor Development  
The analysis of i nhibitor development will be based on the Safety Analysis Set, as defined in 
Section 16.5.1. 
The proportion of subjects who develop an inhibitor during the study will be determined along 
with the exact (Clopper -Pearson) 2 -sided, 95% confidence interval (CI) . The main analysis will 
include all subjects  who have received  at least 1 dose of rFIXFc ( study drug and/ or commercially 
available rFIXFc ). Further analyses will be presented for subjects who reach certain  ED 
milestones, to be specified in the statistical analysis plan. For this latter analysis, both the 
numerator and denominator will include subjects who develop an inhibitor, even if they have not 
reached th e specified  ED milestone.  One ED is defined as a 24-hour period in which a subject 
receives [ADDRESS_77536] injection of rFIXFc defined as the 
start of the ED .  
[IP_ADDRESS]. Adverse Events  
AEs will be coded using the Medical Dictionary for Regulatory Activities. The incidence of AEs 
will be summarized by [CONTACT_6657].  Summaries will be for all AEs as 
well as by [CONTACT_22056].  Subject l istings will be provided for all AEs, 
SAEs, AEs resulting in discontinuation of study treatment and/or from the study, and deaths.  
Unless otherwise specified in the study SAP, AEs and SAEs occurring during treatment with the 
ITI regimen will be summarized  and listed separately.  Serious pretreatment events will be 
included and identified in the SAE listing, but only serious events occurring after the start of treatment will be summarized.   
[IP_ADDRESS]. Other Safety Parameters  
Clinical laboratory values will be summarized for change from baseline, shifts, and potentially 
clinically significant abnormalities.  Threshold levels for potentially clinically significant 
laboratory abnormalities will be provided in the SAP . Listings of abnormal laboratory test results 
will be provided.  
Vital signs will be summarized by [CONTACT_71401].  
Abnormal values will be defined in the SAP . A listing of abnormal vital signs will be provided.   
Duration of exposure and the total number of EDs t o rFIXFc per subject will be summarized 
overall based on the Safety Analysis Set ; selected analyses may be based on the Supporting 
Analysis Set.   
16.6. Interim Analyses  
There are no interim analyses planned for this study.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
84 16.7. Sample Size Considerations  
Hemophilia  B is a rare disease.  Because the size of the hemophilia population is limited, the 
sample size is based on clinical rather than statistical considerations.  Taking into account the 
EMA CHMP Guideline [EMA (EMA/CHMP/BPWP/144552/2009) 2011]  and in an effort to 
enroll a sufficient number of subjects t o assess the efficacy and safety of rFIXFc in this 
population of primarily very young children, approximately [ADDRESS_77537]‚Äôs legally authorized representative (e.g., parent or legal guardian) , as applicable, in 
accordance with local practice and regulations.  If a subject is receiving breast milk from his 
Protocol 998HB303  Version [ADDRESS_77538]  (or the 
subject‚Äôs legally authorized representative) . The subject or his parents/legal guardians must be 
given sufficient time to co nsider whether to participate in the study. 
Subjects or their parents/legal guardians will be informed that the subject‚Äôs race and ethnicity will be collected and will be used during analysis of study results.  See Section  17.4. 
In addition, subjects who have the capacity should provide their assent to participate in the study. The level of information provided to subjects should match their level of understanding as determined by [CONTACT_71402]. 
A copy of the signed and dated  ICF, and assent if applicable, must be given to the subject or the 
subject‚Äôs legally authorized representative.  The original signed and dated ICF will be retained 
with the study records. Local regulations must be complied with in respect to the final 
disposition of the original (wet signature) and copi[INVESTIGATOR_71323].  
Confirmation of informed consent, and assent if applicable,  must also be documented in the 
subject‚Äôs medical record prior to any testing under this protocol, including screening tests and 
assessments.  
Each consent form should contain an authorization allowing the Investigators and Bioverat iv to 
use and disclose protected health information ( PHI, i.e., subject- identifiable health information) 
in compliance with local law.  
17.4. Subject Data Protection  
Prior to any testing under this protocol, including screening tests and assessments, candidates 
(including study subjects and their breastfeeding mothers, if applicable) must also provide all 
authorizations required by [CONTACT_1769] (e.g., PHI authorization in North America). 
During the study, subjects‚Äô race and ethnicity will be collected.  These data may  be used in the 
analysis of the safety and/or pharmacokinetic profile of the study treatment.  Due to the rarity of 
hemophilia B, little is known about differences in the response to FIX products or the occurrence 
of inhibitors across racial and ethnic groups. However, such differences have been noted in patients with hemophilia A.  In cross-sectional analyses of FVIII haplotypes, differences  in the 
occurrence of inhibitors have been observed [Astermark 2005; Carpenter 2012] . Differential 
responses to F VIII products may occur in different haplotypes of F VIII that also differ across 
racial and ethnic groups  [Viel 2009] .  
Study reports will be used for research purposes only. The subject will not be identified by [CONTACT_71403], study-related forms,  study reports, or any related publications. Bioverativ, its 
partner(s) and designee(s), ethics committees, and various government health agencies may 
Protocol 998HB303  Version [ADDRESS_77539]‚Äôs personal medical 
data confidential.  
17.5. Compensation for Injury  
Bioverativ maintains appropriate insurance coverage for clinical trials and will follow applicable 
local compensation laws.  
17.6. Conflict of Interest  
The Investigators should address any potential conflicts of interest (e.g., financial interest  in 
Bioverativ ) with the subject before the subject makes a decision to participate in the study. 
17.7. Registration of Study and Disclosure of Study Results 
Bioverativ  will register the study and post study results  regardless of outcome on a publicly 
accessible website in accordance with the applicable laws and regu lations. 
Protocol 998HB303  Version [ADDRESS_77540] not screen any subjects prior to completion of a study initiation visit, 
conducted by [CONTACT_71404].  This initiation visit will include a detailed review of the 
protocol and study procedures. 
18.2. Quality Assurance  
During and/or after completion of the study, quality assurance officers named by [CONTACT_71405] -site audits or inspections. The Investigator will 
be expected to cooperate with any audit or inspection and  to provide assistance and 
documentation (including source data) as requested. 
18.3. Monitoring of the Study  
The Investigator must permit study -related monitoring by [CONTACT_71406]‚Äô medical histories. 
The Clinical Monitor(s) will visit the Investigator(s) at regular intervals during the study and 
after the study has completed , as appropriate. 
During these visits, eCRFs and supporting documentation related to the study will be reviewed 
and any discrepancies or omissions will be resolved.  
The monitoring visits must be conducted according to the applicable ICH and GCP guidelines to 
ensure protocol adherence, quality of data, study treatment accountability, compliance with regulatory requirements, and continued adequacy of the investigational site and its facilities. 
18.4. Study Funding  
Bioverativ  is the Sponsor of the study and is funding the study. All  financial details are provided 
in the separate contract(s) between the institution , Investigator, and Bioverativ . 
18.5. Publications  
Details are included in the clinical trial agreement for this study.  
Protocol 998HB303  Version [ADDRESS_77541] research organization (CRO) will be responsible for administrative aspects of the 
study including, but not limited to, study initiation, monitoring, management of SAE reports, data management , and the coordination of an independent external DSMC. Before subjects are 
screened at each study site, the CRO will review study responsibilities with the Investigators and other study site staff, as appropriate. 
19.1.2. Interactive Voice and Web Response System  
An IXRS will be used in this study. Before subjects are screened or enrolled, the appropriate 
training will be provided to the study staff by [CONTACT_71407]. A user manual 
will also be provided. Specific details regarding IXRS are provided in the Study Reference Manual. 
19.1.3. Electronic Data Capture 
Subject information will be captured and managed by [CONTACT_71408] a web- based 
electronic data capture tool developed and supported by [CONTACT_71409] . Data should be entered into the electronic data capture 
tool within 5 business days.  
In addition, subjects/ parents/caregivers in the study will have EPDs to record information 
regarding each dose of rFIXFc administered to  the subjec t for any reason at their home or 
locations other than the study site. The subject or the subject‚Äôs parent/caregiver must enter 
dosing information into the EPD as soon as possible after an injection and within a maximum of 7 days following the injection , to ensure data integrity, and to facilitate appropriate medical 
review and dosing guidance. It is recommended that subjects or parents/caregivers enter dosing information immediately after an injection (Section 10.1.2).  
19.1.4. Central Laboratories for Laboratory Assessments 
Central laboratories have been selected by [CONTACT_71410].  Specifics regarding the requirements for laboratory specimen 
collection, handling, and analysis are provided in the Laboratory Manuals.  
19.2. Study Committees  
19.2.1. Independent Data Safety Monitoring Committee  
An independent external DSMC is responsible for evaluating and monitoring the safety and 
tolerability of the study drug on an ongoing basis during the study. The specifics regarding the 
DSMC organization and procedures will be outlined in the DSMC Charter.  
Protocol 998HB303  Version [ADDRESS_77542] consent form may require similar 
modifications (see Sections  17.2 and 17.3). 
19.4. Ethics Committee Notification of Study Completion or Termination  
Where required, the Health Authorities and ethics committees must be notified of completion or 
termination of this study, and sent a copy of the study synopsi s in accordance with necessary 
timelines.  
19.5. Retention of Study Data  
The minimum retention time for study records will meet the strictest standard applicable to that site, as dictated by [CONTACT_65406].  Prior to pr oceeding 
with destruction of records, the Investigator must notify Bioverativ  in writing and receive written 
authorization from Bioverativ  to destroy study records. In addition, the Investigator must notify 
Bioverativ  of any changes in the archival arrange ments including, but not limited to, archival at 
an off-site facility or transfer of ownership if the Investigator leaves the site.  
19.6. Study Report Signatory  
Bioverativ  will designate one of the participating Study Investigators as a signatory for the study 
report. This determination will be made by [CONTACT_71411], including, but not limited to, the Investigator‚Äôs experience and reputation in the studied indication, the Investigator‚Äô s contribution 
to the study in terms of design, management, and/or subject enrollment, or by [CONTACT_71412] . 
Bioverativ  will follow all applicable local regulations pertaining to study report signatories.  
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
91 20. REFERENCES  
Astermark J, Oldenburg J, Escobar M, et al. The Malm√∂ International Brother Study (MIBS). 
Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica. 2005;90(7):924-31. 
Aznar JA, Magall√≥n M, Querol F, et al. The orthopaedic status of severe haemophiliacs in Spain. 
Haemophilia . 2000;6(3):170-6. 
BeneFIX¬Æ [Coagulation Factor IX (Recombinant)] Prescribing Information. Philadelphia, PA: Wyeth Pharmaceuticals, Inc.; Nov 2011. 
Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World 
Health Organ. 1995;73(5):691-701. 
Carpenter SL, Michael Soucie J, Sterner S, et al. Increased prevalence of inhibitors in Hispanic 
patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia. 2012;18(3):e260-5. 
Dimichele D. The North American Immune Tolerance Registry: contributions to the thirty -year 
experience with immune tolerance therapy. Haemophilia. 2009;15(1):320-8. Dumont JA, Low SC, Peters RT, et al. Monomeric Fc fusions: impact on pharmacokinetic and 
biological activity of pro tein therapeutics. BioDrugs. 2006;20(3):151-60. 
European Medicines Agency. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. EMA/CHMP/BPWP/144533/2009. July 21, 2011. 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500
109692.pdf . 
European Medicines Agency. Guideline on clinical investigation of recombinant and human plasma-derived factor IX products. EMA/CHMP/BPWP/144552/2009. July 21, 2011. 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500
109691.pdf . Accessed November 29, 2012. 
European Commission. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population. 2008. p. 34. 
Lambert T, Recht M, Valentino LA, et al. Reformulated BeneFix: efficacy and safety in 
previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007;13(3):233-43. Epub 2007/05/15. 
Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol. 2008;140(4):378-
84. 
Manco-Johnson MJ, Abshire TC, Shapi[INVESTIGATOR_71324], et al. Prophylaxis versus epi[INVESTIGATOR_71325]. N Engl J Med. 2007;357(6):535-44. 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
92 Martinowitz U, Shapi[INVESTIGATOR_2152] A, Quon DV, et al. Pharmacokinetic properties of IB1001, an 
investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia. 2012;18(6):881-7. 
MASAC Recommendation #179 Concerning Prophylaxis (Regular Administration of Clotting 
Factor Concentrate to Prevent Bleeding). November 2007 (Replaces #170). [LOCATION_001], NY: National Hemophilia Foundation. 
http://www.hemophilia.org/NHFWeb/Res ource/StaticPages/menu0/menu5/menu57/masac179.pd
f. Accessed December 03, 2012. 
Molho P, Rolland N, Lebrun T, et al. Epi[INVESTIGATOR_71326] A and B patients in [LOCATION_009]. The French Study Group. [EMAIL_1389] -hop-paris.fr. Haemophilia. 2000;6(1):23-32. 
Monahan PE, Liesner R, Sullivan ST, et al. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia. 2010;16(3):460-8. Epub 2010/01/12. 
Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated 
recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118(10):2695-701. Epub 2011 May 9. Epub 2011/05/11. 
Nilsson IM, Berntorp E, Lofqvist T, et al. Twenty- five years' experience of prophylactic 
treatment in severe haemophilia A and B. J Intern Med. 1992;232(1):25-32. Epub 1992/07/01. Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on 
haemophilia. Bibl Haematol. 1970;34:111-24. Epub 1970/01/01. 
Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 
2006;12(Suppl 6):15-22. 
Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 
2007;7(9):715-25. Epub 2007/08/19. 
Roth DA, Kessler CM, Pasi KJ, et al. Human recombinant factor IX: safety and efficacy studies 
in hemophilia B patients previously treated with plasma -derived factor IX concentrates. Blood. 
2001;98(13):3600-6. 
Santagostino E, Negrier C, Klamroth R, et al. Safety and pharmacokinetics of a novel 
recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012;120(12):2405-11. 
Shapi[INVESTIGATOR_71324], Di Paola J, Cohen A, et al. The safety and efficacy of recombinant human blood 
coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005;105(2):518-25. 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
93 Skinner MW. WFH: Closing the global gap --achieving optimal care. Haemophilia. 2012;[ADDRESS_77543] 4:1-12. 
Viel KR, Ameri A, Abshire TC, et al. Inhibitors of factor VIII in black patients with hemophilia. 
N Engl J Med. 2009;360(16):1618-27. 
WHO. Handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health 
Organization Offset Publication No. 48; 1979. http://whqlibdoc.who.int/offset/WHO_OFFSET_48.pdf
. Accessed November 30, 2012. 
Witmer C, Presley R, Kulkarni R, et al. Associatio ns between intracranial haemorrhage and 
prescribed prophylaxis in a large cohort of haemophilia patients in the [LOCATION_002]. Br J Haematol. 2011;152(2):211-6. 
 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
95 APPENDIX A. rFIXFc DOSING GUIDELINES FO R BLEEDING 
EPI[INVESTIGATOR_71327], analyze, and interpret FIX activity results from the central laboratory.  
Based on this review, the Sponsor will make a recommendation to the Investigator for the 
appropriate dose selection for the corresponding individual and treatment situation. The 
following table describes dosing guidance with rFIXFc for bleeding epi[INVESTIGATOR_1841]. 
DOSING GUIDELINES FOR rFIXFc THERAPY IN HEMOPHILIA B  
Type of Hemorrhage  Factor IX Level Required (%)  
Minor  
Epi[INVESTIGATOR_3940] 25-30 
Hemarthroses, uncomplicated  25-30 
Superficial muscular 25-30 
Superficial soft tissue  25-30 
Moderate  
Epi[INVESTIGATOR_3940] 35-50 
Intramuscular with dissection  35-50 
Soft tissue with dissection 35-50 
Mucous membranes  35-50 
Dental extractions  35-50 
Hematuria  35-50 
Hemarthroses, with limited motion  35-50 
Major  
Epi[INVESTIGATOR_3940] 60-100 
Pharynx 60-100 
Retropharynx 60-100 
Retroperitoneum 60-100 
Surgery 60-100 
Central nervous system  60-100 
 
Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
96 APPENDIX B.  ASSESSMENT  OF RESPONSE  TO BLEEDING 
 
 
 
 
  
  
 
  
 
 
  
 
  
 
 

Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
97 APPENDIX C. PHYSICIAN‚ÄôS GLOBAL ASSESSMENT 
 
 
  
 
  
  
 
  
  
 
 
 
  
  
 
  
  
  

Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
98 APPENDIX D. PHYSICIAN ASSESSMENT  OF RESPONSE TO 
TREATMENT DURING SURGERY 
 
 
 
 
 
  
  
 
  
 
  
  
  
 
 
  
  
  
 
  
  
   
 
 
  

Protocol 998HB303  Version 3 
Safety and Efficacy of rFIXFc in Previously Untreated Patients with Hemophilia B  
CONFIDENTIAL  
The information contained herein may not be used, disclosed, or published without the written consent of Bioverativ 
Therapeutics Inc  
99   
 
  
